1
|
Ananth MR, Gardus JD, Huang C, Palekar N, Slifstein M, Zaborszky L, Parsey RV, Talmage DA, DeLorenzo C, Role LW. Loss of cholinergic input to the entorhinal cortex is an early indicator of cognitive impairment in natural aging of humans and mice. Res Sq 2024:rs.3.rs-3851086. [PMID: 38260541 PMCID: PMC10802688 DOI: 10.21203/rs.3.rs-3851086/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2024]
Abstract
In a series of translational experiments using fully quantitative positron emission tomography (PET) imaging with a new tracer specific for the vesicular acetylcholine transporter ([18F]VAT) in vivo in humans, and genetically targeted cholinergic markers in mice, we evaluated whether changes to the cholinergic system were an early feature of age-related cognitive decline. We found that deficits in cholinergic innervation of the entorhinal cortex (EC) and decline in performance on behavioral tasks engaging the EC are, strikingly, early features of the aging process. In human studies, we recruited older adult volunteers that were physically healthy and without prior clinical diagnosis of cognitive impairment. Using [18F]VAT PET imaging, we demonstrate that there is measurable loss of cholinergic inputs to the EC that can serve as an early signature of decline in EC cognitive performance. These deficits are specific to the cholinergic circuit between the medial septum and vertical limb of the diagonal band (MS/vDB; CH1/2) to the EC. Using diffusion imaging, we further demonstrate impaired structural connectivity in the tracts between the MS/vDB and EC in older adults with mild cognitive impairment. Experiments in mouse, designed to parallel and extend upon the human studies, used high resolution imaging to evaluate cholinergic terminal density and immediate early gene (IEG) activity of EC neurons in healthy aging mice and in mice with genetic susceptibility to accelerated accumulation amyloid beta plaques and hyperphosphorylated mouse tau. Across species and aging conditions, we find that the integrity of cholinergic projections to the EC directly correlates with the extent of EC activation and with performance on EC-related object recognition memory tasks. Silencing EC-projecting cholinergic neurons in young, healthy mice during the object-location memory task impairs object recognition performance, mimicking aging. Taken together we identify a role for acetylcholine in normal EC function and establish loss of cholinergic input to the EC as an early, conserved feature of age-related cognitive decline in both humans and rodents.
Collapse
|
2
|
Weinstein JJ, Moeller SJ, Perlman G, Gil R, Van Snellenberg JX, Wengler K, Meng J, Slifstein M, Abi-Dargham A. Imaging the Vesicular Acetylcholine Transporter in Schizophrenia: A Positron Emission Tomography Study Using [ 18F]-VAT. Biol Psychiatry 2024:S0006-3223(24)00062-3. [PMID: 38309322 DOI: 10.1016/j.biopsych.2024.01.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Revised: 01/10/2024] [Accepted: 01/23/2024] [Indexed: 02/05/2024]
Abstract
BACKGROUND Despite longstanding interest in the central cholinergic system in schizophrenia (SCZ), cholinergic imaging studies with patients have been limited to receptors. Here, we conducted a proof-of-concept positron emission tomography study using [18F]-VAT, a new radiotracer that targets the vesicular acetylcholine transporter as a proxy measure of acetylcholine transmission capacity, in patients with SCZ and explored relationships of vesicular acetylcholine transporter with clinical symptoms and cognition. METHODS A total of 18 adult patients with SCZ or schizoaffective disorder (the SCZ group) and 14 healthy control participants underwent a positron emission tomography scan with [18F]-VAT. Distribution volume (VT) for [18F]-VAT was derived for each region of interest, and group differences in VT were assessed with 2-sample t tests. Functional significance was explored through correlations between VT and scores on the Positive and Negative Syndrome Scale and a computerized neurocognitive battery (PennCNB). RESULTS No group differences in [18F]-VAT VT were observed. However, within the SCZ group, psychosis symptom severity was positively associated with VT in multiple regions of interest, with the strongest effects in the hippocampus, thalamus, midbrain, cerebellum, and cortex. In addition, in the SCZ group, working memory performance was negatively associated with VT in the substantia innominata and several cortical regions of interest including the dorsolateral prefrontal cortex. CONCLUSIONS In this initial study, the severity of 2 important features of SCZ-psychosis and working memory deficit-was strongly associated with [18F]-VAT VT in several cortical and subcortical regions. These correlations provide preliminary evidence of cholinergic activity involvement in SCZ and, if replicated in larger samples, could lead to a more complete mechanistic understanding of psychosis and cognitive deficits in SCZ and the development of therapeutic targets.
Collapse
Affiliation(s)
- Jodi J Weinstein
- Department of Psychiatry and Behavioral Health, Stony Brook University Renaissance School of Medicine, Stony Brook, New York; Department of Psychiatry, Columbia University Vagelos School of Medicine and New York State Psychiatric Institute, New York, New York.
| | - Scott J Moeller
- Department of Psychiatry and Behavioral Health, Stony Brook University Renaissance School of Medicine, Stony Brook, New York
| | - Greg Perlman
- Department of Psychiatry and Behavioral Health, Stony Brook University Renaissance School of Medicine, Stony Brook, New York
| | - Roberto Gil
- Department of Psychiatry and Behavioral Health, Stony Brook University Renaissance School of Medicine, Stony Brook, New York
| | - Jared X Van Snellenberg
- Department of Psychiatry and Behavioral Health, Stony Brook University Renaissance School of Medicine, Stony Brook, New York; Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York; Department of Psychology, Stony Brook University, Stony Brook, New York
| | - Kenneth Wengler
- Department of Psychiatry, Columbia University Vagelos School of Medicine and New York State Psychiatric Institute, New York, New York; Department of Radiology, Stony Brook University Renaissance School of Medicine, Stony Brook, New York
| | - Jiayan Meng
- Department of Psychiatry and Behavioral Health, Stony Brook University Renaissance School of Medicine, Stony Brook, New York
| | - Mark Slifstein
- Department of Psychiatry and Behavioral Health, Stony Brook University Renaissance School of Medicine, Stony Brook, New York
| | - Anissa Abi-Dargham
- Department of Psychiatry and Behavioral Health, Stony Brook University Renaissance School of Medicine, Stony Brook, New York; Department of Psychiatry, Columbia University Vagelos School of Medicine and New York State Psychiatric Institute, New York, New York
| |
Collapse
|
3
|
Hu B, Akula HK, Noh D, Mui YF, Slifstein M, Parsey R, Qu W. An improved synthesis of [ 18 F]VAT and its precursor. J Labelled Comp Radiopharm 2023; 66:384-392. [PMID: 37615234 PMCID: PMC10592132 DOI: 10.1002/jlcr.4059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 08/07/2023] [Accepted: 08/09/2023] [Indexed: 08/25/2023]
Abstract
The vesicular acetylcholine transporter (VAChT) in the brain is an important presynaptic cholinergic biomarker, and neuroimaging studies of VAChT may provide in vivo information about psychiatric and neurologic conditions including Alzheimer's disease that are not accessible by other methods. The 18 F-labeled radiotracer, ((-)-(1-(-8-(2-[18 F]fluoroethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)piperidin-4-yl)(4-fluorophenyl)-methanone ([18 F]VAT, 1), was reported as a selective and high affinity ligand for the in vivo imaging of VAChT. The synthesis of [18 F]VAT has been reported in a two-step procedure with total 140 min, which includes preparation of 2-[18 F]fluoroethyltosylate and alkylation of benzovesamicol (-)-5 precursor with this radiosynthon using two different automated production modules consecutively. A multiple step synthetic route was employed for the synthesis of stereospecific precursor benzovesamicol (-)-5, which is difficult to be adapted for scale-up. To make the production of this tracer more amenable for clinical imaging, we present an improved total synthesis protocol to attain [18 F]VAT: (1) a tosylethoxy group being pre-installed tosylate precursor (-)-8 is synthesized to render a simple one-step radiofluorination under mild conditions; (2) The key optically active intermediate benzovesamicol (-)-5 was obtained via the regio- and enantio-enriched ring-opening amination of meso-epoxide 3 with 4-phenylpiperidine derivative 2 under catalysis of a chiral salenCo(III) catalyst 4b, which dramatically simplifies the synthetic route of the tosylate precursor (-)-8. [18 F]VAT 1 was prepared within ~65 min with desired chemical and radiochemical purities, via a fully automated procedure, using a commercial PET tracer production module. The final drug product was obtained as a sterile, pyrogen-free solution that conforms United States Pharmacopeia (USP) <823> requirements.
Collapse
Affiliation(s)
- Bao Hu
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
- PET Research Core at Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Hari K. Akula
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
- Department of Chemistry, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
- PET Research Core at Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Doyoung Noh
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
- PET Research Core at Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Yiu Fung Mui
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
- PET Research Core at Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Mark Slifstein
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
- PET Research Core at Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Ramin Parsey
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
- PET Research Core at Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Wenchao Qu
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
- Department of Chemistry, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
- PET Research Core at Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| |
Collapse
|
4
|
Williams JC, Zheng ZJ, Tubiolo PN, Luceno JR, Gil RB, Girgis RR, Slifstein M, Abi-Dargham A, Van Snellenberg JX. Medial Prefrontal Cortex Dysfunction Mediates Working Memory Deficits in Patients With Schizophrenia. Biol Psychiatry Glob Open Sci 2023; 3:990-1002. [PMID: 37881571 PMCID: PMC10593895 DOI: 10.1016/j.bpsgos.2022.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 10/04/2022] [Accepted: 10/11/2022] [Indexed: 02/18/2023] Open
Abstract
Background Schizophrenia (SCZ) is marked by working memory (WM) deficits, which predict poor functional outcome. While most functional magnetic resonance imaging studies of WM in SCZ have focused on the dorsolateral prefrontal cortex (PFC), some recent work suggests that the medial PFC (mPFC) may play a role. We investigated whether task-evoked mPFC deactivation is associated with WM performance and whether it mediates deficits in SCZ. In addition, we investigated associations between mPFC deactivation and cortical dopamine release. Methods Patients with SCZ (n = 41) and healthy control participants (HCs) (n = 40) performed a visual object n-back task during functional magnetic resonance imaging. Dopamine release capacity in mPFC was quantified with [11C]FLB457 in a subset of participants (9 SCZ, 14 HCs) using an amphetamine challenge. Correlations between task-evoked deactivation and performance were assessed in mPFC and dorsolateral PFC masks and were further examined for relationships with diagnosis and dopamine release. Results mPFC deactivation was associated with WM task performance, but dorsolateral PFC activation was not. Deactivation in the mPFC was reduced in patients with SCZ relative to HCs and mediated the relationship between diagnosis and WM performance. In addition, mPFC deactivation was significantly and inversely associated with dopamine release capacity across groups and in HCs alone, but not in patients. Conclusions Reduced WM task-evoked mPFC deactivation is a mediator of, and potential substrate for, WM impairment in SCZ, although our study design does not rule out the possibility that these findings could relate to cognition in general rather than WM specifically. We further present preliminary evidence of an inverse association between deactivation during WM tasks and dopamine release capacity in the mPFC.
Collapse
Affiliation(s)
- John C. Williams
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York
- Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York
| | - Zu Jie Zheng
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York
| | - Philip N. Tubiolo
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York
- Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York
| | - Jacob R. Luceno
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York
| | - Roberto B. Gil
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York
- Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, Presbyterian/Columbia University Irving Medical Center, New York, New York
- New York State Psychiatric Institute, New York, New York
| | - Ragy R. Girgis
- Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, Presbyterian/Columbia University Irving Medical Center, New York, New York
- New York State Psychiatric Institute, New York, New York
| | - Mark Slifstein
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York
- Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, Presbyterian/Columbia University Irving Medical Center, New York, New York
- New York State Psychiatric Institute, New York, New York
| | - Anissa Abi-Dargham
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York
- Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York
- Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, Presbyterian/Columbia University Irving Medical Center, New York, New York
- New York State Psychiatric Institute, New York, New York
| | - Jared X. Van Snellenberg
- Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York
- Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York
- Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, Presbyterian/Columbia University Irving Medical Center, New York, New York
- New York State Psychiatric Institute, New York, New York
- Department of Psychology, Stony Brook University, Stony Brook, New York
| |
Collapse
|
5
|
Slifstein M, Abi-Dargham A. Detecting Pharmacologically Induced Serotonin Release in Depression With Positron Emission Tomography Imaging: A New Approach. Biol Psychiatry 2023; 93:1056-1058. [PMID: 37257982 DOI: 10.1016/j.biopsych.2023.04.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 04/11/2023] [Indexed: 06/02/2023]
Affiliation(s)
- Mark Slifstein
- Renaissance School of Medicine, Stony Brook University, Stony Brook, New York.
| | - Anissa Abi-Dargham
- Renaissance School of Medicine, Stony Brook University, Stony Brook, New York
| |
Collapse
|
6
|
Rutherford BR, Choi J, Slifstein M, O'Boyle K, Abi-Dargham A, Brown PJ, Wall MW, Vanegas-Arroyave N, Sakhardande J, Stern Y, Roose SP. Retraction notice to "Neuroanatomical predictors of L-DOPA response in older adults with psychomotor slowing and depression: A pilot study" [J. Affect. Disord. 265 (2020) 439-444]. J Affect Disord 2023; 330:369. [PMID: 36966032 PMCID: PMC10830147 DOI: 10.1016/j.jad.2023.03.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/27/2023]
Affiliation(s)
- Bret R Rutherford
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States
| | - Jongwoo Choi
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States
| | - Mark Slifstein
- Stony Brook University College of Medicine, New York, NY, United States
| | - Kaleigh O'Boyle
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States
| | | | - Patrick J Brown
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States
| | - Melanie W Wall
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States
| | | | - Jayant Sakhardande
- Columbia University College of Physicians and Surgeons, New York, NY, United States
| | - Yaakov Stern
- Columbia University College of Physicians and Surgeons, New York, NY, United States
| | - Steven P Roose
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States
| |
Collapse
|
7
|
Hu B, Akula H, Noh D, Mui YF, Slifstein M, Parsey R, Qu W. An improved synthesis of [18F]VAT precursor for a one-step radiofluorination. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00203-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Akula H, Noh D, Hu B, Mui YF, Parsey R, Slifstein M, Qu W. A facile synthesis of beta-amyloid PET imaging agent [18F]Florbetaben. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00202-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Reinen JM, Whitton AE, Pizzagalli DA, Slifstein M, Abi-Dargham A, McGrath PJ, Iosifescu DV, Schneier FR. Differential reinforcement learning responses to positive and negative information in unmedicated individuals with depression. Eur Neuropsychopharmacol 2021; 53:89-100. [PMID: 34517334 PMCID: PMC8633147 DOI: 10.1016/j.euroneuro.2021.08.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Revised: 07/23/2021] [Accepted: 08/06/2021] [Indexed: 10/20/2022]
Abstract
Major depressive disorder (MDD) is characterized by behavioral and neural abnormalities in processing both rewarding and aversive stimuli, which may impact motivational and affective symptoms. Learning paradigms have been used to assess reinforcement encoding abnormalities in MDD and their association with dysfunctional incentive-based behavior, but how the valence and context of information modulate this learning is not well understood. To address these gaps, we examined responses to positive and negative reinforcement across multiple temporal phases of information processing. While undergoing functional magnetic resonance imaging (fMRI), 47 participants (23 unmedicated, predominantly medication-naïve participants with MDD and 24 demographically-matched HC participants) completed a probabilistic, feedback-based reinforcement learning task that allowed us to separate neural activation during motor response (choice) from reinforcement feedback and monetary outcome across two independent conditions: pursuing gains and avoiding losses. In the gain condition, MDD participants showed overall blunted learning responses (prediction error) in the dorsal striatum when receiving monetary outcome, and reduced responses in ventral striatum for positive, but not negative, prediction error. The MDD group showed enhanced sensitivity to negative information, and symptom severity was associated with better behavioral performance in the loss condition. These findings suggest that striatal responses during learning are abnormal in individuals with MDD but vary with the valence of information.
Collapse
Affiliation(s)
- Jenna M Reinen
- IBM Thomas J. Watson Research Center, Computational Biology Center, Yorktown Heights, NY, United States
| | - Alexis E Whitton
- McLean Hospital and Department of Psychiatry, Harvard Medical School, Belmont, MA, United States; Black Dog Institute, University of New South Wales, Sydney, NSW, Australia
| | - Diego A Pizzagalli
- McLean Hospital and Department of Psychiatry, Harvard Medical School, Belmont, MA, United States
| | - Mark Slifstein
- New York State Psychiatric Institute, 1051 Riverside Drive, Unit 69, New York, NY 10032, United States; Department of Psychiatry, State University of New York at Stony Brook, Stony Brook, NY, United States
| | - Anissa Abi-Dargham
- New York State Psychiatric Institute, 1051 Riverside Drive, Unit 69, New York, NY 10032, United States; Department of Psychiatry, State University of New York at Stony Brook, Stony Brook, NY, United States
| | - Patrick J McGrath
- Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States
| | - Dan V Iosifescu
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Department of Psychiatry, New York University School of Medicine, New York, NY, United States; Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, United States
| | - Franklin R Schneier
- New York State Psychiatric Institute, 1051 Riverside Drive, Unit 69, New York, NY 10032, United States; Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, United States.
| |
Collapse
|
10
|
Oh H, Leung H, Canli T, Slifstein M, Park EY. Associations between psychophysiological stress responses, inflammatory markers, and CSF biomarkers in the spectrum of Alzheimer’s disease. Alzheimers Dement 2021. [DOI: 10.1002/alz.050841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Hwamee Oh
- Brown University Providence RI USA
- Butler Hospital Providence RI USA
- Alpert Medical School of Brown University Providence RI USA
| | - Hoi‐Chung Leung
- The State University of New York at Stony Brook Stony Brook NY USA
| | - Turhan Canli
- The State University of New York at Stony Brook Stony Brook NY USA
| | - Mark Slifstein
- The State University of New York at Stony Brook Stony Brook NY USA
| | - Elliot Y. Park
- Alpert Medical School of Brown University Providence RI USA
| |
Collapse
|
11
|
Deri Y, Clouston SAP, DeLorenzo C, Gardus JD, Bartlett EA, Santiago-Michels S, Bangiyev L, Kreisl WC, Kotov R, Huang C, Slifstein M, Parsey RV, Luft BJ. Neuroinflammation in World Trade Center responders at midlife: A pilot study using [ 18F]-FEPPA PET imaging. Brain Behav Immun Health 2021; 16:100287. [PMID: 34589784 PMCID: PMC8474562 DOI: 10.1016/j.bbih.2021.100287] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Accepted: 06/20/2021] [Indexed: 02/08/2023] Open
Abstract
Background Neuroinflammation has long been theorized to arise from exposures to fine particulate matter and to be modulated when individuals experience chronic stress, both of which are also though to cause cognitive decline in part as a result of neuroinflammation. Objectives Hypothesizing that neuroinflammation might be linked to experiences at the World Trade Center (WTC) events, this study explored associations between glial activation and neuropsychological measures including post-traumatic stress disorder (PTSD) symptom severity and WTC exposure duration. Methods Translocator protein 18-kDa (TSPO) is overexpressed by activated glial cells, predominantly microglia and astrocytes, making TSPO distribution a putative biomarker for neuroinflammation. Twenty WTC responders completed neuropsychological assessments and in vivo PET brain scan with [18F]-FEPPA. Generalized linear modeling was used to test associations between PTSD, and WTC exposure duratiioni as the predictor and both global and regional [18F]-FEPPA total distribution volumes as the outcomes. Result Responders were 56.0 ± 4.7 years-old, and 75% were police officers on 9/11/2001, and all had at least a high school education. Higher PTSD symptom severity was associated with global and regional elevations in [18F]-FEPPA binding predominantly in the hippocampus (d = 0.72, P = 0.001) and frontal cortex (d = 0.64, P = 0.004). Longer exposure duration to WTC sites was associated with higher [18F]-FEPPA binding in the parietal cortex. Conclusion Findings from this study of WTC responders at midlife suggest that glial activation is associated with PTSD symptoms, and WTC exposure duration. Future investigation is needed to understand the important role of neuroinflammation in highly exposed WTC responders. We examined the theory that glial activation is associated with 9/11 exposures. TSPO-Vt was examined using PET in 20 responders adjusting for TSPO genotype. Responders with PTSD had increased TSPO distribution volume in the hippocampus. Heavily exposed responders had increased TSPO distribution in the parietal cortex.
Collapse
Affiliation(s)
- Yael Deri
- Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Sean A P Clouston
- Program in Public Health and Department of Family, Population, and Preventive Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Christine DeLorenzo
- Department of Psychiatry, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.,Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA
| | - John D Gardus
- Department of Psychiatry, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Elizabeth A Bartlett
- Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, NY, USA.,Department of Psychiatry, Columbia University Medical Center, New York, NY, USA
| | - Stephanie Santiago-Michels
- Stony Brook World Trade Center Wellness Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Lev Bangiyev
- Department of Radiology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - William C Kreisl
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA
| | - Roman Kotov
- Department of Psychiatry, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Chuan Huang
- Department of Psychiatry, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.,Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA.,Department of Radiology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Mark Slifstein
- Department of Psychiatry, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| | - Ramin V Parsey
- Department of Psychiatry, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.,Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA
| | - Benjamin J Luft
- Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.,Stony Brook World Trade Center Wellness Program, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
| |
Collapse
|
12
|
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophr Bull 2021; 48:199-210. [PMID: 34423843 PMCID: PMC8781338 DOI: 10.1093/schbul/sbab095] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Decades of research have highlighted the importance of optimal stimulation of cortical dopaminergic receptors, particularly the D1R receptor (D1R), for prefrontal-mediated cognition. This mechanism is particularly relevant to the cognitive deficits in schizophrenia, given the abnormalities in cortical dopamine (DA) neurotransmission and in the expression of D1R. Despite the critical need for D1R-based therapeutics, many factors have complicated their development and prevented this important therapeutic target from being adequately interrogated. Challenges include determination of the optimal level of D1R stimulation needed to improve cognitive performance, especially when D1R expression levels, affinity states, DA levels, and the resulting D1R occupancy by DA, are not clearly known in schizophrenia, and may display great interindividual and intraindividual variability related to cognitive states and other physiological variables. These directly affect the selection of the level of stimulation necessary to correct the underlying neurobiology. The optimal mechanism for stimulation is also unknown and could include partial or full agonism, biased agonism, or positive allosteric modulation. Furthermore, the development of D1R targeting drugs has been complicated by complexities in extrapolating from in vitro affinity determinations to in vivo use. Prior D1R-targeted drugs have been unsuccessful due to poor bioavailability, pharmacokinetics, and insufficient target engagement at tolerable doses. Newer drugs have recently become available, and these must be tested in the context of carefully designed paradigms that address methodological challenges. In this paper, we discuss how a better understanding of these challenges has shaped our proposed experimental design for testing a new D1R/D5R partial agonist, PF-06412562, renamed CVL-562.
Collapse
Affiliation(s)
- Anissa Abi-Dargham
- Department of Psychiatry, Stony Brook Renaissance School of Medicine, Stony Brook, NY, USA,Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA,Department of Psychiatry, Yale University, New Haven, CT, USA,Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA,Cerevel Therapeutics Research and Development, Boston, MA, USA,To whom correspondence should be addressed; Tel: +(631) 885-0814; e-mail:
| | - Jonathan A Javitch
- Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA
| | - Mark Slifstein
- Department of Psychiatry, Stony Brook Renaissance School of Medicine, Stony Brook, NY, USA
| | - Alan Anticevic
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - Monica E Calkins
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Youngsun T Cho
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - Clara Fonteneau
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - Roberto Gil
- Department of Psychiatry, Stony Brook Renaissance School of Medicine, Stony Brook, NY, USA
| | - Ragy Girgis
- Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA
| | - Raquel E Gur
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Ruben C Gur
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Jack Grinband
- Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA
| | - Joshua Kantrowitz
- Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA
| | - Christian Kohler
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - John Krystal
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - John Murray
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | | | | | - Jared Van Snellenberg
- Department of Psychiatry, Stony Brook Renaissance School of Medicine, Stony Brook, NY, USA
| | - Zailyn Tamayo
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - Daniel Wolf
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | | | - David Gray
- Cerevel Therapeutics Research and Development, Boston, MA, USA
| | - Jeffrey Lieberman
- Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA
| |
Collapse
|
13
|
Serrano-Sosa M, Van Snellenberg JX, Meng J, Luceno JR, Spuhler K, Weinstein JJ, Abi-Dargham A, Slifstein M, Huang C. Multitask Learning Based Three-Dimensional Striatal Segmentation of MRI: fMRI and PET Objective Assessments. J Magn Reson Imaging 2021; 54:1623-1635. [PMID: 33970510 DOI: 10.1002/jmri.27682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 04/22/2021] [Accepted: 04/23/2021] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND Recent studies have established a clear topographical and functional organization of projections to and from complex subdivisions of the striatum. Manual segmentation of these functional subdivisions is labor-intensive and time-consuming, and automated methods are not as reliable as manual segmentation. PURPOSE To utilize multitask learning (MTL) as a method to segment subregions of the striatum consisting of pre-commissural putamen (prePU), pre-commissural caudate (preCA), post-commissural putamen (postPU), post-commissural caudate (postCA), and ventral striatum (VST). STUDY TYPE Retrospective. POPULATION Eighty-seven total data sets from patients with schizophrenia and matched controls. FIELD STRENGTH/SEQUENCE 1.5 T and 3.0 T, T1 -weighted (SPGR SENSE, 3D BRAVO). ASSESSMENT MTL-generated segmentations were compared to the Imperial College London Clinical Imaging Center (CIC) atlas. Dice similarity coefficient (DSC) was used to compare the automated methods to manual segmentations. Positron emission tomography (PET) imaging: 60 minutes of emission data were acquired using [11 C]raclopride. Data were reconstructed by filtered back projection (FBP) with computed tomography (CT) used for attenuation correction. Binding potential values, BPND , and region of interest (ROI) time series and whole-brain connectivity using functional magnetic resonance imaging (fMRI) images were compared between manual and both automated segmentations. STATISTICAL TESTS Pearson correlation and paired t-test. RESULTS MTL-generated segmentations showed excellent spatial agreement with manual (DSC ≥0.72 across all striatal subregions). BPND values from MTL-generated segmentations were shown to correlate well with manual segmentations with R2 ≥ 0.91 in all caudate and putamen subregions, and R2 = 0.69 in VST. Mean Pearson correlation coefficients of the fMRI data between MTL-generated and manual segmentations were also high in time series (≥0.86) and whole-brain connectivity (≥0.89) across all subregions. DATA CONCLUSION Across both PET and fMRI task-based assessments, results from MTL-generated segmentations more closely corresponded to results from manually drawn ROIs than CIC-generated segmentations did. Therefore, the proposed MTL approach is a fast and reliable method for three-dimensional striatal subregion segmentation with results comparable to manually segmented ROIs. LEVEL OF EVIDENCE 2 TECHNICAL EFFICACY STAGE: 1.
Collapse
Affiliation(s)
- Mario Serrano-Sosa
- Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York, USA
| | - Jared X Van Snellenberg
- Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York, USA.,Department of Psychiatry and Behavioral Health, Stony Brook Medicine, Stony Brook, New York, USA.,Department of Psychology, Stony Brook University, Stony Brook, New York, USA
| | - Jiayan Meng
- Department of Psychiatry and Behavioral Health, Stony Brook Medicine, Stony Brook, New York, USA
| | - Jacob R Luceno
- Department of Psychiatry and Behavioral Health, Stony Brook Medicine, Stony Brook, New York, USA
| | - Karl Spuhler
- Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York, USA
| | - Jodi J Weinstein
- Department of Psychiatry and Behavioral Health, Stony Brook Medicine, Stony Brook, New York, USA
| | - Anissa Abi-Dargham
- Department of Psychiatry and Behavioral Health, Stony Brook Medicine, Stony Brook, New York, USA
| | - Mark Slifstein
- Department of Psychiatry and Behavioral Health, Stony Brook Medicine, Stony Brook, New York, USA
| | - Chuan Huang
- Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York, USA.,Department of Psychiatry and Behavioral Health, Stony Brook Medicine, Stony Brook, New York, USA.,Department of Radiology, Stony Brook Medicine, Stony Brook, New York, USA
| |
Collapse
|
14
|
Oh H, Leung H, Canli T, Slifstein M. Brain imaging and neuropsychiatric profiles associated with plasma cortisol level among nondemented older adults. Alzheimers Dement 2020. [DOI: 10.1002/alz.041575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Hwamee Oh
- Brown University Providence RI USA
- Butler Hospital Providence RI USA
- Alpert Medical School of Brown University Providence RI USA
| | - Hoi‐Chung Leung
- The State University of New York at Stony Brook Stony Brook NY USA
| | - Turhan Canli
- The State University of New York at Stony Brook Stony Brook NY USA
| | - Mark Slifstein
- The State University of New York at Stony Brook Stony Brook NY USA
| |
Collapse
|
15
|
Knudsen GM, Ganz M, Appelhoff S, Boellaard R, Bormans G, Carson RE, Catana C, Doudet D, Gee AD, Greve DN, Gunn RN, Halldin C, Herscovitch P, Huang H, Keller SH, Lammertsma AA, Lanzenberger R, Liow JS, Lohith TG, Lubberink M, Lyoo CH, Mann JJ, Matheson GJ, Nichols TE, Nørgaard M, Ogden T, Parsey R, Pike VW, Price J, Rizzo G, Rosa-Neto P, Schain M, Scott PJ, Searle G, Slifstein M, Suhara T, Talbot PS, Thomas A, Veronese M, Wong DF, Yaqub M, Zanderigo F, Zoghbi S, Innis RB. Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. J Cereb Blood Flow Metab 2020; 40:1576-1585. [PMID: 32065076 PMCID: PMC7370374 DOI: 10.1177/0271678x20905433] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
It is a growing concern that outcomes of neuroimaging studies often cannot be replicated. To counteract this, the magnetic resonance (MR) neuroimaging community has promoted acquisition standards and created data sharing platforms, based on a consensus on how to organize and share MR neuroimaging data. Here, we take a similar approach to positron emission tomography (PET) data. To facilitate comparison of findings across studies, we first recommend publication standards for tracer characteristics, image acquisition, image preprocessing, and outcome estimation for PET neuroimaging data. The co-authors of this paper, representing more than 25 PET centers worldwide, voted to classify information as mandatory, recommended, or optional. Second, we describe a framework to facilitate data archiving and data sharing within and across centers. Because of the high cost of PET neuroimaging studies, sample sizes tend to be small and relatively few sites worldwide have the required multidisciplinary expertise to properly conduct and analyze PET studies. Data sharing will make it easier to combine datasets from different centers to achieve larger sample sizes and stronger statistical power to test hypotheses. The combining of datasets from different centers may be enhanced by adoption of a common set of best practices in data acquisition and analysis.
Collapse
Affiliation(s)
- Gitte M Knudsen
- Neurobiology Research Unit, Rigshospital and University of Copenhagen, Copenhagen, Denmark
| | - Melanie Ganz
- Neurobiology Research Unit, Rigshospital and University of Copenhagen, Copenhagen, Denmark
| | - Stefan Appelhoff
- Center for Adaptive Rationality, Max Planck Institute for Human Development, Berlin, Germany
| | - Ronald Boellaard
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Guy Bormans
- Laboratory for Radiopharmaceutical Research, KU, Leuven, Belgium
| | - Richard E Carson
- Department of Radiology and Biomedical Imaging, Yale University, New Haven, USA
| | - Ciprian Catana
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital/Harvard Medical School, Department of Radiology, Boston, MA, USA
| | - Doris Doudet
- Department of Medicine/Neurology, Pacific Parkinson Research Center, Vancouver, Canada
| | - Antony D Gee
- Clinical PET Centre, King's College London, London, UK
| | - Douglas N Greve
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital/Harvard Medical School, Department of Radiology, Boston, MA, USA
| | - Roger N Gunn
- Invicro and Division of Brain Sciences, Imperial College London, London, UK
| | - Christer Halldin
- Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden
| | - Peter Herscovitch
- Department of Positron Emission Tomography, National Institutes of Health, Bethesda, USA
| | - Henry Huang
- Department of Radiology and Biomedical Imaging, Yale University, New Haven, USA
| | - Sune H Keller
- Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Adriaan A Lammertsma
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Rupert Lanzenberger
- Department of Psychiatry and Psychotherapy, Medical University of Vienna, Wien, Austria
| | - Jeih-San Liow
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, USA
| | | | - Mark Lubberink
- Uppsala University, Department of Surgical Sciences/Radiology and Nuclear Medicine, Uppsala University Hospital, Department of Medical Physics, Sweden
| | - Chul H Lyoo
- Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
| | - J John Mann
- Department of Psychiatry, Molecular Imaging and Neuropathology Division, Columbia University, New York, USA
| | - Granville J Matheson
- Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden
| | - Thomas E Nichols
- Oxford Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Population Health, University of Oxford, UK
| | - Martin Nørgaard
- Neurobiology Research Unit, Rigshospital and University of Copenhagen, Copenhagen, Denmark
| | - Todd Ogden
- Columbia Mailman School of Public Health, Columbia University, New York, USA
| | - Ramin Parsey
- Department of Psychiatry, School of Medicine, Stony Brook University, Stony Brook, NY, USA
| | - Victor W Pike
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, USA
| | - Julie Price
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital/Harvard Medical School, Department of Radiology, Boston, MA, USA
| | - Gaia Rizzo
- Invicro and Division of Brain Sciences, Imperial College London, London, UK
| | - Pedro Rosa-Neto
- McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada.,Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Montreal, Canada
| | - Martin Schain
- Columbia Mailman School of Public Health, Columbia University, New York, USA
| | - Peter Jh Scott
- Department of Radiology, University of Michigan, Ann Arbor, USA
| | - Graham Searle
- Invicro and Division of Brain Sciences, Imperial College London, London, UK
| | - Mark Slifstein
- Department of Psychiatry, School of Medicine, Stony Brook University, Stony Brook, NY, USA
| | - Tetsuya Suhara
- Institute for Quantum Life Science, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Peter S Talbot
- Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
| | - Adam Thomas
- National Institute of Mental Health, Bethesda, USA
| | - Mattia Veronese
- Centre for Neuroimaging Sciences, King's College London, London, UK
| | - Dean F Wong
- Department of Radiology, Johns Hopkins Hospital, Baltimore, USA
| | - Maqsood Yaqub
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | | | - Sami Zoghbi
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, USA
| | - Robert B Innis
- Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, USA
| |
Collapse
|
16
|
Whitton AE, Reinen JM, Slifstein M, Ang YS, McGrath PJ, Iosifescu DV, Abi-Dargham A, Pizzagalli DA, Schneier FR. Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression. Brain 2020; 143:701-710. [PMID: 32040562 DOI: 10.1093/brain/awaa002] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 11/13/2019] [Accepted: 11/27/2019] [Indexed: 01/05/2023] Open
Abstract
The efficacy of dopamine agonists in treating major depressive disorder has been hypothesized to stem from effects on ventrostriatal dopamine and reward function. However, an important question is whether dopamine agonists are most beneficial for patients with reward-based deficits. This study evaluated whether measures of reward processing and ventrostriatal dopamine function predicted response to the dopamine agonist, pramipexole (ClinicalTrials.gov Identifier: NCT02033369). Individuals with major depressive disorder (n = 26) and healthy controls (n = 26) (mean ± SD age = 26.5 ± 5.9; 50% female) first underwent assessments of reward learning behaviour and ventrostriatal prediction error signalling (measured using functional MRI). 11C-(+)-PHNO PET before and after oral amphetamine was used to assess ventrostriatal dopamine release. The depressed group then received open-label pramipexole treatment for 6 weeks (0.5 mg/day titrated to a maximum daily dose of 2.5 mg). Symptoms were assessed weekly, and reward learning was reassessed post-treatment. At baseline, relative to controls, the depressed group showed lower reward learning (P = 0.02), a trend towards blunted reward-related prediction error signals (P = 0.07), and a trend towards increased amphetamine-induced dopamine release (P = 0.07). Despite symptom improvements following pramipexole (Cohen's d ranging from 0.51 to 2.16 across symptom subscales), reward learning did not change after treatment. At a group level, baseline reward learning (P = 0.001) and prediction error signalling (P = 0.004) were both associated with symptom improvement, albeit in a direction opposite to initial predictions: patients with stronger pretreatment reward learning and reward-related prediction error signalling improved most. Baseline D2/3 receptor availability (P = 0.02) and dopamine release (P = 0.05) also predicted improvements in clinical functioning, with lower D2/3 receptor availability and lower dopamine release predicting greater improvements. Although these findings await replication, they suggest that measures of reward-related mesolimbic dopamine function may hold promise for identifying depressed individuals likely to respond favourably to dopaminergic pharmacotherapy.
Collapse
Affiliation(s)
- Alexis E Whitton
- Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont MA, USA
- Department of Psychiatry, Harvard Medical School, Boston, MA, USA
- School of Medical Sciences, The University of Sydney, Sydney, Australia
| | - Jenna M Reinen
- IBM TJ Watson Research Center, Computational Biology Center, Yorktown Heights, NY, USA
- Department of Psychology, Yale University, New Haven CT, USA
| | - Mark Slifstein
- Division of Translational Imaging, New York State Psychiatric Institute, New York NY, USA
- Department of Psychiatry, Columbia University Medical Center, New York, NY, USA
| | - Yuen-Siang Ang
- Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont MA, USA
- Department of Psychiatry, Harvard Medical School, Boston, MA, USA
| | - Patrick J McGrath
- Department of Psychiatry, Columbia University Medical Center, New York, NY, USA
- Division of Clinical Therapeutics, New York State Psychiatric Institute, New York, NY, USA
| | - Dan V Iosifescu
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Anissa Abi-Dargham
- Division of Translational Imaging, New York State Psychiatric Institute, New York NY, USA
- Department of Psychiatry, Columbia University Medical Center, New York, NY, USA
| | - Diego A Pizzagalli
- Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont MA, USA
- Department of Psychiatry, Harvard Medical School, Boston, MA, USA
| | - Franklin R Schneier
- Department of Psychiatry, Columbia University Medical Center, New York, NY, USA
- Division of Clinical Therapeutics, New York State Psychiatric Institute, New York, NY, USA
| |
Collapse
|
17
|
Girgis RR, Forbes A, Abi-Dargham A, Slifstein M. A positron emission tomography occupancy study of brexpiprazole at dopamine D 2 and D 3 and serotonin 5-HT 1A and 5-HT 2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology 2020; 45:786-792. [PMID: 31847007 PMCID: PMC7075883 DOI: 10.1038/s41386-019-0590-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2019] [Revised: 11/20/2019] [Accepted: 12/05/2019] [Indexed: 11/09/2022]
Abstract
The objective of this study (NCT01854944) was to assess D2/D3, 5-HT1A, 5-HT2A and serotonin transporter (SERT) occupancies of brexpiprazole in adult subjects with schizophrenia in order to identify the in vivo pharmacologic profile that may be relevant to the antipsychotic, antidepressant, and side effect profiles of the drug. Subjects were grouped into three independent cohorts of four subjects each. All subjects underwent positron emission tomography (PET) scans with two different radiotracers at baseline prior to brexpiprazole administration, and again on Day 10 after daily doses of either 4 mg (Cohorts 1 and 2), or 1 mg (Cohort 3). Cohort 1 received scans with [11C]-(+)-PHNO to measure D2 and D3 receptor occupancy and [11C]CUMI101 to measure 5-HT1A occupancy; Cohort 2 received [11C]MDL100907 for 5-HT2A occupancy and [11C]DASB for SERT occupancy; Cohort 3 underwent scanning with [11C]-(+)-PHNO and [11C]MDL100907. Five female and seven male subjects, aged 42 ± 8 years (range, 28-55 years), participated in this study. Dose dependency was observed at D2 receptors, with occupancies reaching 64 ± 8% (mean +/- SD) following 1 mg/day and 80 ± 12% following 4 mg/day. D3 receptor availability increased following 1 mg brexpiprazole treatment and did not change with 4 mg. Robust and dose-related occupancy was also observed at 5-HT2A receptors. Negligible occupancy (<5%) was observed at 5-HT1A and SERT at 4 mg/day. In summary, brexpiprazole demonstrated in vivo binding to D2 receptors and 5-HT2A receptors at steady state after 10 days of daily administration in a dose dependent manner, while binding to D3, 5-HT1A receptors and SERT was not detectable with the radiotracers used for these targets. This pharmacologic profile is consistent with the observed antipsychotic and antidepressant effects.
Collapse
Affiliation(s)
- Ragy R Girgis
- New York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY, USA.
| | - Andy Forbes
- Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA
| | - Anissa Abi-Dargham
- Department of Psychiatry, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA
| | - Mark Slifstein
- Department of Psychiatry, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA
| |
Collapse
|
18
|
Rutherford BR, Choi J, Slifstein M, O'Boyle K, Abi-Dargham A, Brown PJ, Wall MW, Vanegas-Arroyave N, Sakhardande J, Stern Y, Roose SP. Neuroanatomical predictors of L-DOPA response in older adults with psychomotor slowing and depression: A pilot study. J Affect Disord 2020; 265:439-444. [PMID: 32090770 PMCID: PMC7042346 DOI: 10.1016/j.jad.2020.01.066] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Revised: 01/07/2020] [Accepted: 01/15/2020] [Indexed: 12/15/2022]
Abstract
BACKGROUND Declining function in dopamine circuits is implicated in normal aging and late-life depression (LLD). Dopamine augmentation recently has shown therapeutic promise, but predictors of response are unknown. METHODS Depressed elders with slowed gait underwent baseline magnetic resonance imaging (MRI) and [11C]raclopride positron emission tomography (PET). Subjects then received open treatment with carbidopa/levodopa (L-DOPA) for three weeks. Linear regressions examined relationships between baseline MRI measures, [11C]raclopride binding, and behavioral outcomes. RESULTS Among N = 16 participants aged 72.5 ± 6.8 years, higher left superior temporal gyrus volume was associated with higher processing speed at baseline, while cortical thinning in a processing speed network was associated with greater improvement following L-DOPA. Greater volume and cortical thickness in brain regions associated with mobility were associated with higher baseline gait speed. Higher baseline white matter hyperintensity volume predicted less post-L-DOPA improvement on dual task gait speed and IDS-SR scores. Higher [11C]raclopride binding in the associative striatum was associated with cortical thickness in some, but not all, processing speed brain regions, while higher binding in sensorimotor striatum was significantly associated with left caudate volume. LIMITATIONS Limiting the conclusions drawn from this pilot study are the small sample size and open administration of L-DOPA. CONCLUSIONS Greater baseline brain volumes and cortical thickness in regions supporting cognition and gait were associated with higher behavioral performance, while lower structural integrity was associated with increased responsivity to L-DOPA. If substantiated in larger studies, these findings could facilitate the targeting of dopaminergic treatments to those LLD patients most likely to respond.
Collapse
Affiliation(s)
- Bret R Rutherford
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States.
| | - Jongwoo Choi
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States
| | - Mark Slifstein
- Stony Brook University College of Medicine, New York, NY, United States
| | - Kaleigh O'Boyle
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States
| | | | - Patrick J Brown
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States
| | - Melanie W Wall
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States
| | | | - Jayant Sakhardande
- Columbia University College of Physicians and Surgeons, New York, NY, United States
| | - Yaakov Stern
- Columbia University College of Physicians and Surgeons, New York, NY, United States
| | - Steven P Roose
- Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States
| |
Collapse
|
19
|
Slifstein M, Abi-Dargham A, Girgis RR, Suckow RF, Cooper TB, Divgi CR, Sokoloff P, Leriche L, Carberry P, Oya S, Joseph SK, Guiraud M, Montagne A, Brunner V, Gaudoux F, Tonner F. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [ 11C]-(+)-PHNO. Psychopharmacology (Berl) 2020; 237:519-527. [PMID: 31773210 DOI: 10.1007/s00213-019-05387-w] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Accepted: 10/31/2019] [Indexed: 10/25/2022]
Abstract
RATIONALE F17464, a dopamine D3 receptor antagonist with relatively high D3 selectivity (70 fold vs D2 in vitro), exhibits an antipsychotic profile in preclinical studies, and therapeutic efficacy was demonstrated in a randomized placebo-controlled clinical trial in patients with schizophrenia (Bitter et al. Neuropsychopharmacology 44(11):1917-1924, 2019). OBJECTIVE This open-label study in healthy male subjects aimed at characterizing F17464 binding to D3/D2 receptors and the time course of receptor occupancy using positron emission tomography (PET) imaging with a D3-preferring tracer, [11C]-(+)-PHNO. METHODS PET scans were performed at baseline and following a single 30 mg or 15 mg dose of F17464 (3 subjects/dose), and blood samples were collected for pharmacokinetic analysis. Receptor occupancy was calculated based upon reduction in binding potential of the tracer following F17464 administration. The relationship between plasma F17464 concentration and D3/D2 receptor occupancy was modeled and the plasma concentration corresponding to 50% receptor occupancy (EC50) calculated. RESULTS Both doses of F17464 robustly blocked [11C]-(+)-PHNO D3 receptor binding, with substantial occupancy from 1 h post-administration, which increased at 6-9 h (89-98% and 79-87% for the 30 mg and 15 mg groups, respectively) and remained detectable at 22 h. In contrast, D2 binding was only modestly blocked at all time points (< 18%). F17464 exhibited a combination of rapid peripheral kinetics and hysteresis (persistence of binding 22 h post-dose despite low plasma concentration). The best estimate of the EC50 was 19 ng ml-1 (~ 40 nM). CONCLUSION Overall, F17464 was strongly D3-selective in healthy volunteers, a unique profile for an antipsychotic candidate drug.
Collapse
Affiliation(s)
- Mark Slifstein
- Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, 11794, USA. .,Department of Psychiatry, Renaissance School of Medicine, Stony Brook University, HSC T-10-087I Stony Brook, New York, 11794, USA.
| | - Anissa Abi-Dargham
- Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, 11794, USA
| | - Ragy R Girgis
- New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA.,Columbia University College of Physicians & Surgeons, 1051 Riverside Drive, New York, NY, 10032, USA
| | - Raymond F Suckow
- New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA
| | - Thomas B Cooper
- Nathan Kline Research Institute, 140 Old Orangeburg Road, Orangeburg, New York, NY, 10962, USA
| | - Chaitanya R Divgi
- Columbia University Medical Center Kreitchman PET Center, 772 W 168 Street, R-114, New York, NY, 10032, USA
| | | | - Ludovic Leriche
- Institut de Recherche Pierre Fabre (IRPF), 3 avenue Hubert Curien, 31100, Toulouse, France
| | - Patrick Carberry
- Columbia University Medical Center Kreitchman PET Center, 772 W 168 Street, R-114, New York, NY, 10032, USA
| | - Shunichi Oya
- Columbia University Medical Center Kreitchman PET Center, 772 W 168 Street, R-114, New York, NY, 10032, USA
| | - Simon K Joseph
- Columbia University Medical Center Kreitchman PET Center, 772 W 168 Street, R-114, New York, NY, 10032, USA
| | - Marlène Guiraud
- Institut de Recherche Pierre Fabre (IRPF), 3 avenue Hubert Curien, 31100, Toulouse, France
| | - Agnès Montagne
- Institut de Recherche Pierre Fabre (IRPF), 3 avenue Hubert Curien, 31100, Toulouse, France
| | | | - Florence Gaudoux
- Institut de Recherche Pierre Fabre (IRPF), 3 avenue Hubert Curien, 31100, Toulouse, France
| | - Françoise Tonner
- Institut de Recherche Pierre Fabre (IRPF), 3 avenue Hubert Curien, 31100, Toulouse, France
| |
Collapse
|
20
|
Wai JM, Grassetti A, Slifstein M, Matuskey D, Nabulsi N, Ropchan J, Labaree D, Huang Y, Martinez D. Binge alcohol use is not associated with alterations in striatal dopamine receptor binding or dopamine release. Drug Alcohol Depend 2019; 205:107627. [PMID: 31669800 PMCID: PMC6893096 DOI: 10.1016/j.drugalcdep.2019.107627] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Revised: 09/05/2019] [Accepted: 09/08/2019] [Indexed: 01/03/2023]
Abstract
BACKGROUND Previous imaging studies using Positron Emission Tomography (PET) have shown that alcohol use disorder (AUD) is associated with a decrease in dopamine type 2/3 receptor (D2/3) binding and dopamine transmission. Although binge drinking is a risk factor for future AUD, little is known about the neurobiology of binge drinking in young adults. This study measured D2/3 receptor binding and stimulant-induced dopamine release using PET and [11C]raclopride in binge drinkers without an AUD. METHODS This study included 14 healthy controls (HC) and 14 young adult binge drinkers (BD), aged 18-25. The BD met National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for binge drinking and the HC subjects were social drinkers. The subjects were scanned with [11C]raclopride before and after the administration of oral methylphenidate (60 mg) to measure D2/3 binding and dopamine release. RESULTS There was no significant difference in the PET measures of D2/3 binding or methylphenidate-induced dopamine release between the two groups. There was no significant association between Alcohol Use Disorders Identification Test (AUDIT) scores or 30-day drinking history and the imaging data. CONCLUSION In this sample of 18-25-year-old binge drinkers without a diagnosis of a substance use disorder, there were no significant differences in D2/3 receptor binding potential or methylphenidate-induced dopamine release relative to healthy controls.
Collapse
Affiliation(s)
- Jonathan M. Wai
- Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons and the New York State Psychiatric Institute, 1051 Riverside Drive, Unit 66, New York, NY 10038, USA,Corresponding author. (J.M. Wai)
| | - Alexander Grassetti
- Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons and the New York State Psychiatric Institute, 1051 Riverside Drive, Unit 66, New York, NY 10038, USA
| | - Mark Slifstein
- Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons and the New York State Psychiatric Institute, 1051 Riverside Drive, Unit 66, New York, NY 10038, USA
| | - David Matuskey
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510, USA
| | - Nabeel Nabulsi
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510, USA
| | - Jim Ropchan
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510, USA
| | - David Labaree
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510, USA
| | - Yiyun Huang
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510, USA
| | - Diana Martinez
- Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons and the New York State Psychiatric Institute, 1051 Riverside Drive, Unit 66, New York, NY 10038, USA
| |
Collapse
|
21
|
Martinez D, Slifstein M, Matuskey D, Nabulsi N, Zheng MQ, Lin SF, Ropchan J, Urban N, Grassetti A, Chang D, Salling M, Foltin R, Carson RE, Huang Y. Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study. Neuropsychopharmacology 2019; 44:1720-1727. [PMID: 31026862 PMCID: PMC6785004 DOI: 10.1038/s41386-019-0398-4] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 03/28/2019] [Accepted: 04/16/2019] [Indexed: 01/08/2023]
Abstract
Animal studies indicate that the kappa-opioid receptor/dynorphin system plays an important role in cocaine binges and stress-induced relapse. Our goal was to investigate changes in kappa-opioid receptor (KOR) availability in the human brain using positron emission tomography (PET), before and after a cocaine binge. We also investigated the correlation between KOR and stress-induced cocaine self-administration. PET imaging was performed with the KOR selective agonist [11C]GR103545. Subjects with cocaine-use disorder (CUD) underwent PET scans and performed two types of cocaine self-administration sessions in the laboratory as follows: (1) choice sessions following a cold pressor test, to induce stress, and (2) binge dosing of cocaine. This allowed us investigate the following: (1) the association between KOR binding and a laboratory model of stress-induced relapse and (2) the change in KOR binding following a 3-day cocaine binge, which is thought to represent a change in endogenous dynorphin. A group of matched healthy controls was included to investigate between group differences in KOR availability. A significant association between [11C]GR103545 binding and cocaine self-administration was seen: greater KOR availability was associated with more choices for cocaine. In addition, the 3-day cocaine binge significantly reduced [11C]GR103545 binding by 18% in the striatum and 14% across brain regions. No difference in [11C]GR103545 binding was found between the CUD subjects and matched controls. In the context of previous studies, these findings add to the growing evidence that pharmacotherapies targeting the KOR have the potential to significantly impact treatment development for cocaine-use disorder.
Collapse
Affiliation(s)
- Diana Martinez
- Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, USA.
| | - Mark Slifstein
- Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, USA
| | - David Matuskey
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Nabeel Nabulsi
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Ming-Qiang Zheng
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Shu-Fei Lin
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Jim Ropchan
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Nina Urban
- Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, USA
| | - Alexander Grassetti
- Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, USA
| | - Dinnisa Chang
- Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, USA
| | - Michael Salling
- Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, USA
| | - Richard Foltin
- Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, USA
| | - Richard E Carson
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| | - Yiyun Huang
- Yale PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA
| |
Collapse
|
22
|
Rutherford BR, Slifstein M, Chen C, Abi-Dargham A, Brown PJ, Wall MW, Vanegas-Arroyave N, Stern Y, Bailey V, Valente E, Roose SP. RETRACTED: Effects of L-DOPA Monotherapy on Psychomotor Speed and [ 11C]Raclopride Binding in High-Risk Older Adults With Depression. Biol Psychiatry 2019; 86:221-229. [PMID: 31178096 PMCID: PMC6641997 DOI: 10.1016/j.biopsych.2019.04.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Revised: 03/22/2019] [Accepted: 04/04/2019] [Indexed: 01/28/2023]
Abstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of Biological Psychiatry Editor John H. Krystal, M.D., with agreement from all authors except Chen Chen and Emily Valente. These two co-authors moved and, with no forwarding information that was available or could be found, they were therefore unable to be contacted. The authors have uncovered irregularities and deviations from the approved protocol related to the work reported in this article. Treatment with antidepressant medications within the past 28 days was an exclusion criterion: “Subjects were excluded for… current treatment or treatment within the past 4 weeks with psychotropic or other medications known to affect dopamine.” Individuals taking an ineffective antidepressant medication who otherwise met study criteria were to undergo a study-supervised medication taper to discontinue their medication for the required period prior to study participation. The published article does not describe that a subgroup of participants (15 out of the 47 consented subjects) enrolled in the study while taking an ineffective antidepressant medication. Of this subgroup, 10 individuals were successfully tapered off their medication and were among the 36 subjects contributing data to the analyses described. In addition, the authors have found that 8 participants did not complete the required 28-day washout prior to beginning the study. For these 8 participants, the medication-free period ranged from 1 to 21 days, with a mean of 10.1 days. Separately, an inclusion criterion was that eligible subjects “had Center for Epidemiologic Studies—Depression Rating scale score ≤ 10.” However, the authors have found that 3 ineligible participants were included, each of whom had depressive symptom scores 1 point out of range for eligibility. Lastly, the CONSORT diagram in Figure S1 states that 11 participants were lost to follow-up. However, this is incorrect. Instead, 9 participants were lost to follow up and 2 participants were screen failures. The authors voluntarily informed the Journal of these honest errors upon discovery. Because of the extent of these issues, the editors and authors concluded that the only course of action was to retract this paper. However, the authors are revising the paper, which the Journal will consider further for publication.
Collapse
Affiliation(s)
- Bret R Rutherford
- Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York.
| | - Mark Slifstein
- Stony Brook University Renaissance College of Medicine, Stony Brook, New York
| | - Chen Chen
- Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York
| | - Anissa Abi-Dargham
- Stony Brook University Renaissance College of Medicine, Stony Brook, New York
| | - Patrick J Brown
- Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York
| | - Melanie W Wall
- Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York
| | | | - Yaakov Stern
- Columbia University Vagelos College of Physicians and Surgeons, New York, New York
| | | | - Emily Valente
- New York State Psychiatric Institute, New York, New York
| | - Steven P Roose
- Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York
| |
Collapse
|
23
|
Korner J, Cline GW, Slifstein M, Barba P, Rayat GR, Febres G, Leibel RL, Maffei A, Harris PE. A role for foregut tyrosine metabolism in glucose tolerance. Mol Metab 2019; 23:37-50. [PMID: 30876866 PMCID: PMC6479665 DOI: 10.1016/j.molmet.2019.02.008] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2019] [Revised: 02/14/2019] [Accepted: 02/24/2019] [Indexed: 01/13/2023] Open
Abstract
Objective We hypothesized that DA and L-DOPA derived from nutritional tyrosine and the resultant observed postprandial plasma excursions of L-DOPA and DA might affect glucose tolerance via their ability to be taken-up by beta cells and inhibit glucose-stimulated β-cell insulin secretion. Methods To investigate a possible circuit between meal-stimulated 3,4-dihydroxy-L-phenylalanine (L-DOPA) and dopamine (DA) production in the GI tract and pancreatic β-cells, we: 1) mapped GI mucosal expression of tyrosine hydroxylase (TH) and aromatic amino acid decarboxylase (AADC); 2) measured L-DOPA and DA content of GI mucosal tissues following meal challenges with different L-tyrosine (TYR) content, 3) determined whether meal TYR content impacts plasma insulin and glucose excursions; and 4) characterized postprandial plasma excursions of L-DOPA and DA in response to meal tyrosine content in rodents and a population of bariatric surgery patients. Next, we characterized: 1) the metabolic transformation of TYR and L-DOPA into DA in vitro using purified islet tissue; 2) the metabolic transformation of orally administrated stable isotope labeled TYR into pancreatic DA, and 3) using a nuclear medicine technique, we studied endocrine beta cells in situ release and binding of DA in response to a glucose challenge. Results We demonstrate in rodents that intestinal content and circulatory concentrations L-DOPA and DA, plasma glucose and insulin are responsive to the tyrosine (TYR) content of a test meal. Intestinal expression of two enzymes, Tyrosine hydroxylase (TH) and Aromatic Amino acid Decarboxylase (AADC), essential to the transformation of TYR to DA was mapped and the metabolism of metabolism of TYR to DA was traced in human islets and a rodent beta cell line in vitro and from gut to the pancreas in vivo. Lastly, we show that β cells secrete and bind DA in situ in response to glucose stimulation. Conclusions We provide proof-of-principle evidence for the existence of a novel postprandial circuit of glucose homeostasis dependent on nutritional tyrosine. DA and L-DOPA derived from nutritional tyrosine may serve to defend against hypoglycemia via inhibition of glucose-stimulated β-cell insulin secretion as proposed by the anti-incretin hypothesis. Nutritional tyrosine is metabolized to L DOPA and DA in the foregut. Postprandial L-DOPA and DA plasma concentrations rise in response to tyrosine. Oral stable isotope labeled tyrosine is found postprandially in the pancreas as DA. L-DOPA and DA are inhibitors of beta cell glucose-stimulated insulin secretion. Postprandial L-DOPA and DA excursions are muted in certain bariatric surgery patients.
Collapse
Affiliation(s)
- Judith Korner
- Department of Medicine and the Naomi Berrie Diabetes Center, Columbia University, College of Physicians and Surgeons, New York, NY, 10032, USA
| | - Gary W Cline
- Yale Diabetes Research Center, Yale School of Medicine, New Haven, CT, 06520, USA
| | - Mark Slifstein
- Department of Psychiatry, Stony Brook University, Stony Brook, New York, NY, 11794, USA
| | - Pasquale Barba
- Institute of Genetics and Biophysics, Adriano Buzzati-Traverso, CNR, Naples, IT 80131, Italy
| | - Gina R Rayat
- Alberta Diabetes Institute, Ray Rajotte Surgical-Medical Research Institute, Department of Surgery, University of Alberta, Edmonton, AB, T6G 2E1 CA, Canada
| | - Gerardo Febres
- Department of Medicine and the Naomi Berrie Diabetes Center, Columbia University, College of Physicians and Surgeons, New York, NY, 10032, USA
| | - Rudolph L Leibel
- Department of Medicine and the Naomi Berrie Diabetes Center, Columbia University, College of Physicians and Surgeons, New York, NY, 10032, USA
| | - Antonella Maffei
- Department of Medicine and the Naomi Berrie Diabetes Center, Columbia University, College of Physicians and Surgeons, New York, NY, 10032, USA
| | - Paul E Harris
- Department of Medicine and the Naomi Berrie Diabetes Center, Columbia University, College of Physicians and Surgeons, New York, NY, 10032, USA.
| |
Collapse
|
24
|
Nørgaard M, Ganz M, Svarer C, Feng L, Ichise M, Lanzenberger R, Lubberink M, Parsey RV, Politis M, Rabiner EA, Slifstein M, Sossi V, Suhara T, Talbot PS, Turkheimer F, Strother SC, Knudsen GM. Cerebral serotonin transporter measurements with [ 11C]DASB: A review on acquisition and preprocessing across 21 PET centres. J Cereb Blood Flow Metab 2019; 39:210-222. [PMID: 29651896 PMCID: PMC6365604 DOI: 10.1177/0271678x18770107] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Positron Emission Tomography (PET) imaging has become a prominent tool to capture the spatiotemporal distribution of neurotransmitters and receptors in the brain. The outcome of a PET study can, however, potentially be obscured by suboptimal and/or inconsistent choices made in complex processing pipelines required to reach a quantitative estimate of radioligand binding. Variations in subject selection, experimental design, data acquisition, preprocessing, and statistical analysis may lead to different outcomes and neurobiological interpretations. We here review the approaches used in 105 original research articles published by 21 different PET centres, using the tracer [11C]DASB for quantification of cerebral serotonin transporter binding, as an exemplary case. We highlight and quantify the impact of the remarkable variety of ways in which researchers are currently conducting their studies, while implicitly expecting generalizable results across research groups. Our review provides evidence that the foundation for a given choice of a preprocessing pipeline seems to be an overlooked aspect in modern PET neuroscience. Furthermore, we believe that a thorough testing of pipeline performance is necessary to produce reproducible research outcomes, avoiding biased results and allowing for better understanding of human brain function.
Collapse
Affiliation(s)
- Martin Nørgaard
- 1 Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.,2 Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Melanie Ganz
- 1 Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.,3 Department of Computer Science, University of Copenhagen, Copenhagen, Denmark
| | - Claus Svarer
- 1 Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Ling Feng
- 1 Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Masanori Ichise
- 4 Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Rupert Lanzenberger
- 5 Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
| | - Mark Lubberink
- 6 Department of Nuclear Medicine and Positron Emission Tomography, Uppsala University, Uppsala, Sweden
| | - Ramin V Parsey
- 7 Department of Psychiatry, School of Medicine, Stony Brook University, Stony Brook, NY, USA
| | - Marios Politis
- 8 Neurodegeneration Imaging Group, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK
| | - Eugenii A Rabiner
- 9 Imanova Limited, London, UK.,10 Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Mark Slifstein
- 7 Department of Psychiatry, School of Medicine, Stony Brook University, Stony Brook, NY, USA
| | - Vesna Sossi
- 11 Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada
| | - Tetsuya Suhara
- 4 Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
| | - Peter S Talbot
- 12 Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
| | | | - Stephen C Strother
- 14 Rotman Research Institute at Baycrest, University of Toronto, Toronto, Canada
| | - Gitte M Knudsen
- 1 Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.,2 Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
25
|
Schneier FR, Slifstein M, Whitton AE, Pizzagalli DA, Reinen J, McGrath PJ, Iosifescu DV, Abi-Dargham A. Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [ 11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study. Biol Psychiatry 2018; 84:563-573. [PMID: 30041971 PMCID: PMC6347467 DOI: 10.1016/j.biopsych.2018.05.014] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Revised: 05/02/2018] [Accepted: 05/15/2018] [Indexed: 12/22/2022]
Abstract
BACKGROUND Mesolimbic dopamine system dysfunction is believed to contribute to major depressive disorder (MDD), but molecular neuroimaging of striatal dopamine neurotransmission has yielded mixed results, possibly owing to limited sensitivity of antagonist radioligands used with positron emission tomography to assess dopamine release capacity. This study used an agonist radioligand with agonist challenge to assess dopamine release capacity and D2/D3 receptor availability in MDD. METHODS Twenty-six treatment-naive adults with MDD and 26 healthy comparison participants underwent functional magnetic resonance imaging during a probabilistic reinforcement task, and positron emission tomography with the D3-preferring ligand [11C]-(+)-PHNO, before and after oral dextroamphetamine. MDD participants then received pramipexole treatment for 6 weeks. RESULTS MDD participants had trend-level greater dopamine release capacity in the ventral striatum, as measured by percent change in baseline binding potential relative to nondisplaceable compartment (ΔBPND) (-34% vs. -30%; p = .072, d = 0.58) but no difference in D2/D3 receptor availability (BPND). Striatal and extrastriatal BPND and percent change in baseline BPND were not significantly associated with blood oxygen level-dependent response to reward prediction error in the ventral striatum, severity of depression and anhedonia, or antidepressant response to pramipexole (response rate = 72.7%). CONCLUSIONS [11C]-(+)-PHNO demonstrated high sensitivity to displacement by amphetamine-induced dopamine release, but dopamine release capacity and D2/D3 availability were not associated with ventral striatal activation to reward prediction error or clinical features, in this study powered to detect large effects. While a preponderance of indirect evidence implicates dopaminergic dysfunction in MDD, these findings suggest that presynaptic dopamine dysregulation may not be a feature of MDD or a prerequisite for treatment response to dopamine agonists.
Collapse
Affiliation(s)
- Franklin R Schneier
- Division of Clinical Therapeutics, New York State Psychiatric Institute, Columbia University Medical Center, New York, New York; Department of Psychiatry, Columbia University Medical Center, New York, New York.
| | - Mark Slifstein
- Division of Translational Imaging, New York State Psychiatric Institute, Columbia University Medical Center, New York, New York; Department of Psychiatry, Columbia University Medical Center, New York, New York
| | - Alexis E Whitton
- Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont; Department of Psychiatry, Harvard Medical School, Cambridge, Massachusetts
| | - Diego A Pizzagalli
- Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont; Department of Psychiatry, Harvard Medical School, Cambridge, Massachusetts
| | - Jenna Reinen
- Department of Psychology, Columbia University Medical Center, New York, New York; Department of Psychology, Yale University, New Haven, Connecticut
| | - Patrick J McGrath
- Division of Clinical Therapeutics, New York State Psychiatric Institute, Columbia University Medical Center, New York, New York; Department of Psychiatry, Columbia University Medical Center, New York, New York
| | - Dan V Iosifescu
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Anissa Abi-Dargham
- Division of Translational Imaging, New York State Psychiatric Institute, Columbia University Medical Center, New York, New York; Department of Psychiatry, Columbia University Medical Center, New York, New York
| |
Collapse
|
26
|
Weinstein JJ, van de Giessen E, Rosengard RJ, Xu X, Ojeil N, Brucato G, Gil RB, Kegeles LS, Laruelle M, Slifstein M, Abi-Dargham A. PET imaging of dopamine-D2 receptor internalization in schizophrenia. Mol Psychiatry 2018; 23:1506-1511. [PMID: 28507321 PMCID: PMC5690884 DOI: 10.1038/mp.2017.107] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2017] [Revised: 03/22/2017] [Accepted: 04/04/2017] [Indexed: 02/07/2023]
Abstract
Recent genetic, molecular and post-mortem studies suggest impaired dopamine (DA)-D2 receptor (D2R) trafficking in patients with schizophrenia (SZ). Imaging and preclinical studies have shown agonist-induced D2R internalization can be imaged with positron emission tomography (PET) using D2R radiotracers combined with psychostimulant challenge. This is feasible if radiotracer binding is measured when postchallenge DA levels have returned to baseline, following the initial competition phase between DA and radiotracer for binding to D2R. Here we used 'late-phase' imaging after challenge to test the hypothesis that impaired D2R internalization in SZ leads to blunted late-phase displacement, or a faster return to baseline, in patients compared with healthy controls (HCs). We imaged 10 patients with SZ and 9 HCs with PET and [11C]raclopride at baseline and two times (3-5 and 6-10 h) following 0.5 mg kg-1 dextroamphetamine. We measured binding potential relative to non-displaceable compartment (BPND) and derived percent reduction from baseline (ΔBPND) for each postamphetamine scan. To test the hypothesis that time course of return of striatal BPND to baseline differed between SZ and HCs, we implemented a linear model with ΔBPND as dependent variable, time after amphetamine as repeated measure and time after amphetamine and diagnostic group as fixed effects. Neither diagnostic group nor interaction of diagnostic group-by-time after amphetamine significantly affected striatal ΔBPND (F=1.38, P=0.26; F=0.51, P=0.61). These results show similar pattern of return of BPND to baseline as a function of time in patients with SZ and HC, suggesting that striatal D2R internalization as measured by our imaging paradigm is normal in patients with SZ.
Collapse
Affiliation(s)
- Jodi J. Weinstein
- Department of Psychiatry, Stony Brook University School of Medicine, Stony Brook, New York,Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York
| | | | | | - Xiaoyan Xu
- New York State Psychiatric Institute, New York, New York
| | - Najate Ojeil
- New York State Psychiatric Institute, New York, New York
| | - Gary Brucato
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York,New York State Psychiatric Institute, New York, New York
| | - Roberto B. Gil
- Department of Psychiatry, Stony Brook University School of Medicine, Stony Brook, New York
| | - Lawrence S. Kegeles
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York,New York State Psychiatric Institute, New York, New York
| | - Marc Laruelle
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York
| | - Mark Slifstein
- Department of Psychiatry, Stony Brook University School of Medicine, Stony Brook, New York
| | - Anissa Abi-Dargham
- Department of Psychiatry, Stony Brook University School of Medicine, Stony Brook, New York
| |
Collapse
|
27
|
Kegeles LS, Horga G, Ghazzaoui R, Rosengard R, Ojeil N, Xu X, Slifstein M, Petrakis I, O'Malley SS, Krystal JH, Abi-Dargham A. Enhanced Striatal Dopamine Release to Expectation of Alcohol: A Potential Risk Factor for Alcohol Use Disorder. Biol Psychiatry Cogn Neurosci Neuroimaging 2018; 3:591-598. [PMID: 29803635 DOI: 10.1016/j.bpsc.2018.03.018] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2017] [Revised: 03/07/2018] [Accepted: 03/26/2018] [Indexed: 01/08/2023]
Abstract
BACKGROUND We used positron emission tomography imaging with [11C]raclopride to examine the effects of consumption of alcohol or placebo beverage by participants with alcohol use disorder (AUD) compared with healthy participants with and without family history of AUD. We sought to assess dopamine release following alcohol exposure in relation to AUD risk. METHODS Three groups were enrolled: participants with AUD (n = 15) and healthy participants with family history negative (n = 34) or positive (n = 16) for AUD. Participants consumed a placebo (n = 65) or alcohol (n = 63) beverage in counterbalanced order before positron emission tomography scanning (128 scans). Binding potential (BPND) in the two drink conditions and the percent change in BPND between conditions were evaluated across striatal subregions. Subjective effects of beverage consumption were rated. Effects of group, drink order, and sex were evaluated. RESULTS Alcohol resulted in greater dopamine release than did placebo in the ventral striatum (p < .001). There were no main effects of group, drink order, or sex on ventral striatum BPND or percent change in BPND. However, there was a drink order-by-group interaction (p = .02) whereby family history-positive participants who received placebo first had both lower placebo BPND and less difference between placebo and alcohol BPND than all other groups, consistent with expectation of alcohol powerfully evoking dopamine release in this group. Subjective responses showed the same order-by-group interaction. CONCLUSIONS Hyper-responsivity of the dopaminergic system in family history-positive participants to expectation of alcohol may contribute to the expression of familial risk for AUD.
Collapse
Affiliation(s)
- Lawrence S Kegeles
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, New York; Department of Radiology, Columbia University College of Physicians and Surgeons, New York, New York.
| | - Guillermo Horga
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, New York
| | - Rassil Ghazzaoui
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, New York
| | - Rachel Rosengard
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, New York
| | - Najate Ojeil
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, New York
| | - Xiaoyan Xu
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, New York
| | - Mark Slifstein
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, New York
| | - Ismene Petrakis
- Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut
| | | | - John H Krystal
- Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut
| | - Anissa Abi-Dargham
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, New York; Department of Radiology, Columbia University College of Physicians and Surgeons, New York, New York
| |
Collapse
|
28
|
Slifstein M, Abi-Dargham A. Is it Pre- or Postsynaptic? Imaging Striatal Dopamine Excess in Schizophrenia. Biol Psychiatry 2018; 83:635-637. [PMID: 29559095 DOI: 10.1016/j.biopsych.2018.02.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Revised: 02/12/2018] [Accepted: 02/22/2018] [Indexed: 02/07/2023]
Affiliation(s)
- Mark Slifstein
- Department of Psychiatry, Stony Brook University, Stony Brook, New York.
| | | |
Collapse
|
29
|
Cassidy CM, Balsam PD, Weinstein JJ, Rosengard RJ, Slifstein M, Daw ND, Abi-Dargham A, Horga G. A Perceptual Inference Mechanism for Hallucinations Linked to Striatal Dopamine. Curr Biol 2018; 28:503-514.e4. [PMID: 29398218 PMCID: PMC5820222 DOI: 10.1016/j.cub.2017.12.059] [Citation(s) in RCA: 95] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Revised: 11/23/2017] [Accepted: 12/29/2017] [Indexed: 12/14/2022]
Abstract
Hallucinations, a cardinal feature of psychotic disorders such as schizophrenia, are known to depend on excessive striatal dopamine. However, an underlying cognitive mechanism linking dopamine dysregulation and the experience of hallucinatory percepts remains elusive. Bayesian models explain perception as an optimal combination of prior expectations and new sensory evidence, where perceptual distortions such as illusions and hallucinations may occur if prior expectations are afforded excessive weight. Such excessive weight of prior expectations, in turn, could stem from a gain-control process controlled by neuromodulators such as dopamine. To test for such a dopamine-dependent gain-control mechanism of hallucinations, we studied unmedicated patients with schizophrenia with varying degrees of hallucination severity and healthy individuals using molecular imaging with a pharmacological manipulation of dopamine, structural imaging, and a novel task designed to measure illusory changes in the perceived duration of auditory stimuli under different levels of uncertainty. Hallucinations correlated with a perceptual bias, reflecting disproportional gain on expectations under uncertainty. This bias could be pharmacologically induced by amphetamine, strongly correlated with striatal dopamine release, and related to cortical volume of the dorsal anterior cingulate, a brain region involved in tracking environmental uncertainty. These findings outline a novel dopamine-dependent mechanism for perceptual modulation in physiological conditions and further suggest that this mechanism may confer vulnerability to hallucinations in hyper-dopaminergic states underlying psychosis.
Collapse
Affiliation(s)
- Clifford M Cassidy
- Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; The Royal's Institute of Mental Health Research, University of Ottawa, 1145 Carling Avenue, Ottawa, ON K1Z 7K4, Canada
| | - Peter D Balsam
- Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; Department of Psychology, Columbia University, 3009 Broadway, New York, NY 10027, USA
| | - Jodi J Weinstein
- Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; Department of Psychiatry, Stony Brook University, 100 Nicholls Road, Stony Brook, NY 11794, USA
| | - Rachel J Rosengard
- Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, 1051 Riverside Drive, New York, NY 10032, USA
| | - Mark Slifstein
- Department of Psychiatry, Stony Brook University, 100 Nicholls Road, Stony Brook, NY 11794, USA
| | - Nathaniel D Daw
- Department of Psychology, Princeton University, South Drive, Princeton, NJ 08540, USA
| | - Anissa Abi-Dargham
- Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, 1051 Riverside Drive, New York, NY 10032, USA; Department of Psychiatry, Stony Brook University, 100 Nicholls Road, Stony Brook, NY 11794, USA
| | - Guillermo Horga
- Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, 1051 Riverside Drive, New York, NY 10032, USA.
| |
Collapse
|
30
|
Weinstein JJ, van de Giessen E, Rosengard RJ, Xu X, Ojeil N, Brucato G, Gil RB, Kegeles LS, Laruelle M, Slifstein M, Abi-Dargham A. PET imaging of dopamine-D2 receptor internalization in schizophrenia. Mol Psychiatry 2017:mp2017157. [PMID: 29155803 DOI: 10.1038/mp.2017.157] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
This corrects the article DOI: 10.1038/mp.2017.107.
Collapse
|
31
|
Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A. Pathway-Specific Dopamine Abnormalities in Schizophrenia. Biol Psychiatry 2017; 81:31-42. [PMID: 27206569 PMCID: PMC5177794 DOI: 10.1016/j.biopsych.2016.03.2104] [Citation(s) in RCA: 185] [Impact Index Per Article: 26.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Revised: 03/21/2016] [Accepted: 03/25/2016] [Indexed: 02/08/2023]
Abstract
In light of the clinical evidence implicating dopamine in schizophrenia and the prominent hypotheses put forth regarding alterations in dopaminergic transmission in this disease, molecular imaging has been used to examine multiple aspects of the dopaminergic system. We review the imaging methods used and compare the findings across the different molecular targets. Findings have converged to suggest early dysregulation in the striatum, especially in the rostral caudate, manifesting as excess synthesis and release. Recent data showed deficit extending to most cortical regions and even to other extrastriatal subcortical regions not previously considered to be "hypodopaminergic" in schizophrenia. These findings yield a new topography for the dopaminergic dysregulation in schizophrenia. We discuss the dopaminergic innervation within the individual projection fields to provide a topographical map of this dual dysregulation and explore potential cellular and circuit-based mechanisms for brain region-dependent alterations in dopaminergic parameters. This refined knowledge is essential to better guide translational studies and efforts in early drug development.
Collapse
Affiliation(s)
- Jodi J. Weinstein
- Columbia University Department of Psychiatry, New York, NY,New York State Psychiatric Institute Division of Translational Imaging,Corresponding author: Jodi Weinstein, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 31, New York, New York 10032, +1-646-774-8123,
| | - Muhammad O. Chohan
- New York State Psychiatric Institute Division of Integrative Neuroscience
| | - Mark Slifstein
- Columbia University Department of Psychiatry, New York, NY,New York State Psychiatric Institute Division of Translational Imaging
| | - Lawrence S. Kegeles
- Columbia University Department of Psychiatry, New York, NY,New York State Psychiatric Institute Division of Translational Imaging
| | - Holly Moore
- Columbia University Department of Psychiatry, New York, NY,New York State Psychiatric Institute Division of Integrative Neuroscience
| | - Anissa Abi-Dargham
- Columbia University Department of Psychiatry, New York, NY,New York State Psychiatric Institute Division of Translational Imaging
| |
Collapse
|
32
|
Van Snellenberg JX, Girgis RR, Horga G, van de Giessen E, Slifstein M, Ojeil N, Weinstein JJ, Moore H, Lieberman JA, Shohamy D, Smith EE, Abi-Dargham A. Mechanisms of Working Memory Impairment in Schizophrenia. Biol Psychiatry 2016; 80:617-26. [PMID: 27056754 PMCID: PMC4995154 DOI: 10.1016/j.biopsych.2016.02.017] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Revised: 02/15/2016] [Accepted: 02/16/2016] [Indexed: 11/19/2022]
Abstract
BACKGROUND The neural correlates of working memory (WM) impairment in schizophrenia remain a key puzzle in understanding the cognitive deficits and dysfunction of dorsolateral prefrontal cortex observed in this disorder. We sought to determine whether patients with schizophrenia exhibit an alteration in the inverted-U relationship between WM load and activation that we recently observed in healthy individuals and whether this could account for WM deficits in this population. METHODS Medicated (n = 30) and unmedicated (n = 21) patients with schizophrenia and healthy control subjects (n = 45) performed the self-ordered WM task during functional magnetic resonance imaging. We identified regions exhibiting an altered fit to an inverted-U relationship between WM load and activation that were also predictive of WM performance. RESULTS A blunted inverted-U response was observed in left dorsolateral prefrontal cortex in patients and was associated with behavioral deficits in WM capacity. In addition, suppression of medial prefrontal cortex during WM was reduced in patients and was associated with poorer WM capacity in patients. Finally, activation of visual cortex in the cuneus was elevated in patients and associated with improved WM capacity. Together, these findings explained 55% of the interindividual variance in WM capacity when combined with diagnostic and medication status, which alone accounted for only 22% of the variance in WM capacity. CONCLUSIONS These findings identify a novel biomarker and putative mechanism of WM deficits in patients with schizophrenia, a reduction or flattening of the inverted-U relationship between activation and WM load observed in healthy individuals in left dorsolateral prefrontal cortex.
Collapse
Affiliation(s)
- Jared X Van Snellenberg
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; Divisions of Translational Imaging, New York, New York; Cognitive Neuroscience, New York, New York.
| | - Ragy R Girgis
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; Divisions of Translational Imaging, New York, New York
| | - Guillermo Horga
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; Divisions of Translational Imaging, New York, New York
| | - Elsmarieke van de Giessen
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; Divisions of Translational Imaging, New York, New York; Department of Nuclear Medicine, University of Amsterdam, Amsterdam, The Netherlands
| | - Mark Slifstein
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; Divisions of Translational Imaging, New York, New York
| | - Najate Ojeil
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; Divisions of Translational Imaging, New York, New York
| | - Jodi J Weinstein
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; Divisions of Translational Imaging, New York, New York
| | - Holly Moore
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; Integrative Neuroscience, New York, New York
| | - Jeffrey A Lieberman
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York
| | - Daphna Shohamy
- Department of Psychology, Columbia University, New York, New York
| | - Edward E Smith
- Cognitive Neuroscience, New York, New York; Department of Psychology, Columbia University, New York, New York
| | - Anissa Abi-Dargham
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; Divisions of Translational Imaging, New York, New York
| |
Collapse
|
33
|
Abstract
Molecular imaging with PET or SPECT has been an important research tool in psychiatry for as long as these modalities have been available. Here, we discuss two areas of neuroimaging relevant to current psychiatry research. The first is the use of imaging to study neurotransmission. We discuss the use of pharmacologic probes to induce changes in levels of neurotransmitters that can be inferred through their effects on outcome measures of imaging experiments, from their historical origins focusing on dopamine transmission through recent developments involving serotonin, GABA, and glutamate. Next, we examine imaging of neuroinflammation in the context of psychiatry. Imaging markers of neuroinflammation have been studied extensively in other areas of brain research, but they have more recently attracted interest in psychiatry research, based on accumulating evidence that there may be an inflammatory component to some psychiatric conditions. Furthermore, new probes are under development that would allow unprecedented insights into cellular processes. In summary, molecular imaging would continue to offer great potential as a unique tool to further our understanding of brain function in health and disease.
Collapse
Affiliation(s)
- Mark Slifstein
- Department of Psychiatry, Columbia University Medical Center, New York, NY; New York State Psychiatric Institute, New York, NY; Department of Psychiatry, Stony Brook University, New York, NY.
| | - Anissa Abi-Dargham
- Department of Psychiatry, Columbia University Medical Center, New York, NY; Department of Radiology, Columbia University Medical Center, New York, NY; New York State Psychiatric Institute, New York, NY; Department of Psychiatry, Stony Brook University, New York, NY
| |
Collapse
|
34
|
Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl) 2016; 233:3503-12. [PMID: 27525990 PMCID: PMC5035321 DOI: 10.1007/s00213-016-4382-y] [Citation(s) in RCA: 88] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Accepted: 07/10/2016] [Indexed: 01/01/2023]
Abstract
RATIONALE Second-generation antipsychotics occupy dopamine D2 receptors and act as antagonists or partial agonists at these receptors. While these drugs alleviate positive symptoms in patients with schizophrenia, they are less effective for treating cognitive deficits and negative symptoms. Dopamine D3 receptors are highly expressed in areas of the brain thought to play a role in the regulation of motivation and reward-related behavior. Consequently, the dopamine D3 receptor has become a target for treating negative symptoms in combination with D2 antagonism to treat positive symptoms in patients with schizophrenia. OBJECTIVE The purpose of this study was to determine the cariprazine receptor occupancies in brain for D2 and D3 receptors in patients with schizophrenia. METHODS Using [(11)C]-(+)-PHNO as a radioligand, positron emission tomography (PET) scans were performed in eight patients at baseline and postdose on days 1, 4, and 15. Plasma and cerebrospinal fluid (CSF) samples were analyzed for cariprazine concentrations. RESULTS A monotonic dose-occupancy relationship was observed for both receptor types. After 2 weeks of treatment, near complete (∼100 %) occupancies were observed for both receptors at a dose of 12 mg/day. At the lowest cariprazine dose (1 mg/day), mean D3 and D2 receptor occupancies were 76 and 45 %, respectively, suggesting selectivity for D3 over D2 receptors at low doses. An exposure-response analysis found a ∼3-fold difference in EC50 (D3 = 3.84 nM and D2 = 13.03 nM) in plasma after 2 weeks of dosing. CONCLUSION This PET imaging study in patients with schizophrenia demonstrated that cariprazine is a D3-preferring dual D3/D2 receptor partial agonist.
Collapse
Affiliation(s)
- Ragy R Girgis
- Department of Psychiatry, New York State Psychiatric Institute, Columbia University, 1051 Riverside Drive Unit 31, New York, NY, 10032, USA.
- New York State Psychiatric Institute (NYSPI), Columbia University Medical Center, New York, NY, USA.
| | - Mark Slifstein
- New York State Psychiatric Institute (NYSPI), Columbia University Medical Center, New York, NY, USA
| | - Deepak D'Souza
- Clinical Neuroscience Research Unit (CNRU), Yale School of Medicine, New Haven, CT, USA
- Department of Psychiatry, Yale University School of Medicine, Yale PET Center, New Haven, CT, USA
| | - Yih Lee
- Forest Research Institute, Jersey City, NJ, USA
- Pharmaceutical Product Development, LLC, Richmond, VA, 23230, USA
| | | | | | | | | | - Nika Adham
- Forest Research Institute, Jersey City, NJ, USA
| | - Nabeel Nabulsi
- Department of Psychiatry, Yale University School of Medicine, Yale PET Center, New Haven, CT, USA
| | - Yiyun Huang
- Department of Psychiatry, Yale University School of Medicine, Yale PET Center, New Haven, CT, USA
| | - Richard E Carson
- Department of Psychiatry, Yale University School of Medicine, Yale PET Center, New Haven, CT, USA
| | - Béla Kiss
- Gedeon Richter Plc., Budapest, Hungary
| | | | - Anissa Abi-Dargham
- New York State Psychiatric Institute (NYSPI), Columbia University Medical Center, New York, NY, USA
| | | |
Collapse
|
35
|
Horga G, Cassidy CM, Xu X, Moore H, Slifstein M, Van Snellenberg JX, Abi-Dargham A. Dopamine-Related Disruption of Functional Topography of Striatal Connections in Unmedicated Patients With Schizophrenia. JAMA Psychiatry 2016; 73:862-70. [PMID: 27145361 PMCID: PMC5310843 DOI: 10.1001/jamapsychiatry.2016.0178] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE Despite the well-established role of striatal dopamine in psychosis, current views generally agree that cortical dysfunction is likely necessary for the emergence of psychotic symptoms. The topographic organization of striatal-cortical connections is central to gating and integration of higher-order information, so a disruption of such topography via dysregulated dopamine could lead to cortical dysfunction in schizophrenia. However, this hypothesis remains to be tested using multivariate methods ascertaining the global pattern of striatal connectivity and without the confounding effects of antidopaminergic medication. OBJECTIVES To examine whether the pattern of brain connectivity across striatal subregions is abnormal in unmedicated patients with schizophrenia and whether this abnormality relates to psychotic symptoms and extrastriatal dopaminergic transmission. DESIGN, SETTING, AND PARTICIPANTS In this multimodal, case-control study, we obtained resting-state functional magnetic resonance imaging data from 18 unmedicated patients with schizophrenia and 24 matched healthy controls from the New York State Psychiatric Institute. A subset of these (12 and 17, respectively) underwent positron emission tomography with the dopamine D2 receptor radiotracer carbon 11-labeled FLB457 before and after amphetamine administration. Data were acquired between June 16, 2011, and February 25, 2014. Data analysis was performed from September 1, 2014, to January 11, 2016. MAIN OUTCOMES AND MEASURES Group differences in the striatal connectivity pattern (assessed via multivariable logistic regression) across striatal subregions, the association between the multivariate striatal connectivity pattern and extrastriatal baseline D2 receptor binding potential and its change after amphetamine administration, and the association between the multivariate connectivity pattern and the severity of positive symptoms evaluated with the Positive and Negative Syndrome Scale. RESULTS Of the patients with schizophrenia (mean [SEM] age, 35.6 [11.8] years), 9 (50%) were male and 9 (50%) were female. Of the controls (mean [SEM] age, 33.7 [8.8] years), 10 (42%) were male and 14 (58%) were female. Patients had an abnormal pattern of striatal connectivity, which included abnormal caudate connections with a distributed set of associative cortex regions (χ229 = 53.55, P = .004). In patients, more deviation from the multivariate pattern of striatal connectivity found in controls correlated specifically with more severe positive symptoms (ρ = -0.77, P = .002). Striatal connectivity also correlated with baseline binding potential across cortical and extrastriatal subcortical regions (t25 = 3.01, P = .01, Bonferroni corrected) but not with its change after amphetamine administration. CONCLUSIONS AND RELEVANCE Using a multimodal, circuit-level interrogation of striatal-cortical connections, it was demonstrated that the functional topography of these connections is globally disrupted in unmedicated patients with schizophrenia. These findings suggest that striatal-cortical dysconnectivity may underlie the effects of dopamine dysregulation on the pathophysiologic mechanism of psychotic symptoms.
Collapse
Affiliation(s)
- Guillermo Horga
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York,Division of Translational Imaging, New York State Psychiatric Institute, New York, New York,Please address correspondence to Guillermo Horga, MD, PhD, at New York State Psychiatric Institute, Columbia University Medical Center, Unit 31, 1051 Riverside Dr., New York, NY 10032, or
| | - Clifford M. Cassidy
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York,Division of Translational Imaging, New York State Psychiatric Institute, New York, New York
| | - Xiaoyan Xu
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York,Division of Translational Imaging, New York State Psychiatric Institute, New York, New York
| | - Holly Moore
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York,Division of Integrative Neuroscience, New York State Psychiatric Institute, New York, New York
| | - Mark Slifstein
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York,Division of Translational Imaging, New York State Psychiatric Institute, New York, New York
| | - Jared X. Van Snellenberg
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York,Division of Translational Imaging, New York State Psychiatric Institute, New York, New York
| | - Anissa Abi-Dargham
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York,Division of Translational Imaging, New York State Psychiatric Institute, New York, New York
| |
Collapse
|
36
|
Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, Cho RY, Carter CS, Slifstein M, Abi-Dargham A, Lieberman JA. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J Psychopharmacol 2016; 30:428-35. [PMID: 26966119 DOI: 10.1177/0269881116636120] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND Evidence from preclinical and human studies indicates the presence of reduced dopamine-1 receptor (D1R) signaling in the cortex, where D1Rs predominate, in patients with schizophrenia (SCZ), which may contribute to their cognitive deficits. Furthermore, studies in nonhuman primates (NHP) have suggested that intermittent administration of low doses of D1R agonists produce long-lasting reversals in cognitive deficits. The purpose of this trial was to test whether a similar design, involving subacute intermittent administration of low doses of a full, selective agonist at D1Rs, DAR-0100A, would improve cognitive deficits in SCZ. METHODS We randomized 49 clinically stable individuals with SCZ to three weeks of intermittent treatment with 0.5 mg or 15 mg of DAR-0100A, or placebo (normal saline). Functional magnetic resonance imaging (fMRI) BOLD was used to evaluate the effects of drug administration on brain activity during a working memory (WM) task. Effects on cognition were also assessed using the MATRICS and the N-back task as primary endpoints. The CogState battery was used as a secondary endpoint. RESULTS There were no observed treatment effects on either the BOLD fMRI signal during WM tasks or the WM domains of the MATRICS. Moderate improvement was detected on the CogState battery and on the attention domain of the MATRICS. CONCLUSION These results suggest that low doses of D1 agonists that do not result in measureable occupancy of the D1R do not reliably improve cognition in SCZ, unlike the observations in NHP. As this drug is limited by its pharmacokinetic profile, better D1R agonists that can achieve adequate levels of D1R occupancy are needed to test the efficacy of this mechanism for cognitive enhancement in SCZ.
Collapse
Affiliation(s)
- Ragy R Girgis
- Department of Psychiatry, Columbia University, New York, NY, USA New York State Psychiatric Institute, New York, NY, USA
| | - Jared X Van Snellenberg
- Department of Psychiatry, Columbia University, New York, NY, USA New York State Psychiatric Institute, New York, NY, USA
| | - Andrew Glass
- Department of Psychiatry, Columbia University, New York, NY, USA New York State Psychiatric Institute, New York, NY, USA
| | - Lawrence S Kegeles
- Department of Psychiatry, Columbia University, New York, NY, USA New York State Psychiatric Institute, New York, NY, USA
| | - Judy L Thompson
- Department of Psychiatry, Columbia University, New York, NY, USA New York State Psychiatric Institute, New York, NY, USA Rutgers University, New Brunswick, NJ, USA
| | - Melanie Wall
- Department of Psychiatry, Columbia University, New York, NY, USA New York State Psychiatric Institute, New York, NY, USA
| | - Raymond Y Cho
- Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Cameron S Carter
- Department of Psychiatry and Behavioral Sciences, University of California-Davis, Sacramento, CA, USA
| | - Mark Slifstein
- Department of Psychiatry, Columbia University, New York, NY, USA New York State Psychiatric Institute, New York, NY, USA
| | - Anissa Abi-Dargham
- Department of Psychiatry, Columbia University, New York, NY, USA New York State Psychiatric Institute, New York, NY, USA Department of Radiology, Columbia University, New York, NY, USA
| | - Jeffrey A Lieberman
- Department of Psychiatry, Columbia University, New York, NY, USA New York State Psychiatric Institute, New York, NY, USA
| |
Collapse
|
37
|
|
38
|
Girgis RR, Xu X, Gil RB, Hackett E, Ojeil N, Lieberman JA, Slifstein M, Abi-Dargham A. Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [(11)C]-(+)-PHNO. Schizophr Res 2015; 168:373-6. [PMID: 26190300 PMCID: PMC4591174 DOI: 10.1016/j.schres.2015.06.027] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Revised: 06/25/2015] [Accepted: 06/29/2015] [Indexed: 11/29/2022]
Abstract
BACKGROUND All currently available antipsychotic medications bind to both the dopamine-2 (D2) and dopamine-3 (D3) receptors in vitro. However, there is conflicting evidence from in vivo studies about whether or not antipsychotic medications bind to the D3 receptor (D3R). The purpose of this study was to determine whether acute doses of risperidone bind to the D3R in humans. METHODS We performed PET scans on an mCT scanner with [(11)C]-(+)-PHNO injected as a bolus, before and after a 2mg oral dose of risperidone in five medication free subjects with schizophrenia. The subjects were scanned for 120min and underwent an MRI scan for region of interest delineation and coregistration. Cerebellum was used as a reference region. Simplified reference tissue modeling (SRTM) was used to calculate BPND. RESULTS We observed binding to the D3R receptor by risperidone as evidenced by observable occupancy in regions in which the [(11)C]-(+)-PHNO signal is almost exclusively from the D3R (i.e., substantia nigra/ventral tegmental area). Using a regression model to estimate D2R:D3R selectivity, we observed a D2R:D3R selectivity of 2.1 for risperidone. CONCLUSION Our preliminary results provide further support that acute doses of antipsychotic medications bind to the D3R and provide additional support for the further development of this receptor as a treatment target in schizophrenia.
Collapse
Affiliation(s)
- Ragy R. Girgis
- Corresponding author, Tel. +1 646 774 5553; fax: +1 212 568 6171.
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Broft A, Slifstein M, Osborne J, Kothari P, Morim S, Shingleton R, Kenney L, Vallabhajosula S, Attia E, Martinez D, Timothy Walsh B. Striatal dopamine type 2 receptor availability in anorexia nervosa. Psychiatry Res 2015; 233:380-7. [PMID: 26272038 PMCID: PMC5055757 DOI: 10.1016/j.pscychresns.2015.06.013] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2015] [Revised: 04/23/2015] [Accepted: 06/27/2015] [Indexed: 12/31/2022]
Abstract
The neurobiology of anorexia nervosa remains incompletely understood. Here we utilized PET imaging with the radiotracer [(11)C]raclopride to measure striatal dopamine type 2 (D2) receptor availability in patients with anorexia nervosa. 25 women with anorexia nervosa who were receiving treatment in an inpatient program participated, as well as 25 control subjects. Patients were scanned up to two times with the PET tracer [(11)C]raclopride: once while underweight, and once upon weight restoration. Control subjects underwent one PET scan. In the primary analyses, there were no significant differences between underweight patients (n=21) and control subjects (n=25) in striatal D2 receptor binding potential. Analysis of subregions (sensorimotor striatum, associative striatum, limbic striatum) did not reveal differences between groups. In patients completing both scans (n=15), there were no detectable changes in striatal D2 receptor binding potential after weight restoration. In this sample, there were no differences in striatal D2 receptor binding potential between patients with anorexia nervosa and control subjects. Weight restoration was not associated with a change in striatal D2 receptor binding. These findings suggest that disturbances in reward processing in this disorder are not attributable to abnormal D2 receptor characteristics, and that other reward-related neural targets may be of greater relevance.
Collapse
Affiliation(s)
- Allegra Broft
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA.
| | - Mark Slifstein
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA
| | - Joseph Osborne
- Weill Cornell Medical College, Department of Radiology, New York, NY, USA; Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY, USA
| | - Paresh Kothari
- Weill Cornell Medical College, Department of Radiology, New York, NY, USA
| | - Simon Morim
- Weill Cornell Medical College, Department of Radiology, New York, NY, USA
| | - Rebecca Shingleton
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA; Boston University, Department of Psychology, Boston, MA, USA
| | - Lindsay Kenney
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA
| | | | - Evelyn Attia
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA
| | - Diana Martinez
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA
| | - B Timothy Walsh
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA
| |
Collapse
|
40
|
Simpson HB, Kegeles LS, Hunter L, Mao X, Van Meter P, Xu X, Kimeldorf MB, Pearlstein SL, Slifstein M, Shungu DC. Assessment of glutamate in striatal subregions in obsessive-compulsive disorder with proton magnetic resonance spectroscopy. Psychiatry Res 2015; 232:65-70. [PMID: 25715904 PMCID: PMC4404189 DOI: 10.1016/j.pscychresns.2015.01.009] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Revised: 10/14/2014] [Accepted: 01/10/2015] [Indexed: 01/24/2023]
Abstract
Glutamatergic signaling abnormalities in cortico-striatal circuits are hypothesized to lead to the repetitive thoughts and behaviors of obsessive-compulsive disorder (OCD). To test this hypothesis, studies have used proton magnetic resonance spectroscopy (1H MRS) to measure glutamatergic compounds in the striatum of individuals with OCD. However, no studies have used methods that could measure glutamate minimally contaminated by glutamine and γ-aminobutyric acid (GABA) in striatal subregions. Therefore, in this study, a proton MRS imaging (1H MRSI) technique with relatively high spatial resolution at 3.0 T was used to measure minimally contaminated glutamate levels in three striatal subregions (i.e., dorsal caudate, dorsal putamen, and ventral striatum) in 15 unmedicated adults with OCD and 16 matched healthy control subjects. No significant group differences in glutamate levels were found in any of the three striatal subregions. In contrast, a study in unmedicated pediatric OCD patients that measured glutamatergic compounds in the dorsal caudate by MRS at 1.5 T found significant elevations. Further studies are warranted to assess whether these discrepant MRS findings are due to differences in subject age or MRS methodology, or potentially are associated with glutamatergic gene variants implicated in OCD.
Collapse
Affiliation(s)
- Helen Blair Simpson
- Department of Psychiatry at Columbia University Medical Center, College of Physicians and Surgeons, Columbia University, New York, NY, United States; Division of Clinical Therapeutics at the New York State Psychiatric Institute, New York, NY, United States.
| | - Lawrence S. Kegeles
- Department of Psychiatry at Columbia University Medical Center, College of Physicians and Surgeons, Columbia University, New York, NY, United States,Department of Radiology at Columbia University Medical Center, College of Physicians and Surgeons, Columbia University, New York, NY, United States,Division of Translational Imaging at the New York State Psychiatric Institute, New York, NY, United States
| | - Liane Hunter
- Division of Clinical Therapeutics at the New York State Psychiatric Institute, New York, NY, United States
| | - Xiangling Mao
- Department of Radiology, Weill Cornell Medical College, New York, NY, United States
| | - Page Van Meter
- Division of Clinical Therapeutics at the New York State Psychiatric Institute, New York, NY, United States
| | - Xiaoyan Xu
- Division of Translational Imaging at the New York State Psychiatric Institute, New York, NY, United States
| | - Marcia B. Kimeldorf
- Division of Clinical Therapeutics at the New York State Psychiatric Institute, New York, NY, United States
| | - Sarah L. Pearlstein
- Division of Clinical Therapeutics at the New York State Psychiatric Institute, New York, NY, United States
| | - Mark Slifstein
- Department of Psychiatry at Columbia University Medical Center, College of Physicians and Surgeons, Columbia University, New York, NY, United States,Division of Translational Imaging at the New York State Psychiatric Institute, New York, NY, United States
| | - Dikoma C. Shungu
- Department of Radiology, Weill Cornell Medical College, New York, NY, United States
| |
Collapse
|
41
|
Hwang DR, Hu E, Allen JR, Davis C, Treanor J, Miller S, Chen H, Shi B, Narayanan TK, Barret O, Alagille D, Yu Z, Slifstein M. Radiosynthesis and initial characterization of a PDE10A specific PET tracer [18F]AMG 580 in non-human primates. Nucl Med Biol 2015; 42:654-63. [PMID: 25935386 DOI: 10.1016/j.nucmedbio.2015.04.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Revised: 03/12/2015] [Accepted: 04/10/2015] [Indexed: 01/02/2023]
Abstract
INTRODUCTION Phosphodiesterase 10A (PDE10A) is an intracellular enzyme responsible for the breakdown of cyclic nucleotides which are important second messengers for neurotransmission. Inhibition of PDE10A has been identified as a potential target for treatment of various neuropsychiatric disorders. To assist drug development, we have identified a selective PDE10A positron emission tomography (PET) tracer, AMG 580. We describe here the radiosynthesis of [(18)F]AMG 580 and in vitro and in vivo characterization results. METHODS The potency and selectivity were determined by in vitro assay using [(3)H]AMG 580 and baboon brain tissues. [(18)F]AMG 580 was prepared by a 1-step [(18)F]fluorination procedure. Dynamic brain PET scans were performed in non-human primates. Regions-of-interest were defined on individuals' MRIs and transferred to the co-registered PET images. Data were analyzed using two tissue compartment analysis (2TC), Logan graphical (Logan) analysis with metabolite-corrected input function and the simplified reference tissue model (SRTM) method. A PDE10A inhibitor and unlabeled AMG 580 were used to demonstrate the PDE10A specificity. KD was estimated by Scatchard analysis of high and low affinity PET scans. RESULTS AMG 580 has an in vitro KD of 71.9 pM. Autoradiography showed specific uptake in striatum. Mean activity of 121 ± 18 MBq was used in PET studies. In Rhesus, the baseline BPND for putamen and caudate was 3.38 and 2.34, respectively, via 2TC, and 3.16, 2.34 via Logan, and 2.92, and 2.01 via SRTM. A dose dependent decrease of BPND was observed by the pre-treatment with a PDE10A inhibitor. In baboons, 0.24 mg/kg dose of AMG 580 resulted in about 70% decrease of BPND. The in vivo KD of [(18)F]AMG 580 was estimated to be around 0.44 nM in baboons. CONCLUSION [(18)F]AMG 580 is a selective and potent PDE10A PET tracer with excellent specific striatal binding in non-human primates. It warrants further evaluation in humans.
Collapse
Affiliation(s)
- Dah-Ren Hwang
- Medical Sciences, 271 Running Water Ct, Ambler, PA 19002.
| | - Essa Hu
- Small Molecule Chemistry, Amgen Inc., Thousand Oaks, CA, USA
| | | | - Carl Davis
- Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, CA, USA
| | | | - Silke Miller
- Neuroscience, Amgen Inc., Thousand Oaks, CA, USA
| | - Hang Chen
- Neuroscience, Amgen Inc., South San Francisco, USA
| | - Bingzhi Shi
- Department of Nuclear Medicine, Kettering Medical Center, Kettering, OH, USA
| | | | | | | | - Zhigang Yu
- Medical Sciences, 271 Running Water Ct, Ambler, PA 19002.
| | - Mark Slifstein
- Department of Psychiatry, Columbia University, New York, NY, USA; New York State Psychiatric Institute, NY, USA
| |
Collapse
|
42
|
Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D’Souza D, Malison RT, Huang Y, Lim KP, Nabulsi N, Carson RE, Lieberman JA, Abi-Dargham A. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 2015; 72:316-24. [PMID: 25651194 PMCID: PMC4768742 DOI: 10.1001/jamapsychiatry.2014.2414] [Citation(s) in RCA: 259] [Impact Index Per Article: 28.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE Multiple lines of evidence suggest a deficit in dopamine release in the prefrontal cortex (PFC) in schizophrenia. Despite the prevalence of the concept of prefrontal cortical hypodopaminergia in schizophrenia, in vivo imaging of dopamine release in the PFC has not been possible until now, when the validity of using the positron emission tomographic D2/3 radiotracer carbon 11-labeled FLB457 in combination with the amphetamine paradigm was clearly established. OBJECTIVES To (1) test amphetamine-induced dopamine release in the dorsolateral PFC (DLPFC) in drug-free or drug-naive patients with schizophrenia (SCZ) and healthy control (HC) individuals matched for age, sex, race/ethnicity, and familial socioeconomic status;(2) test blood oxygenation level-dependent (BOLD) functional magnetic resonance imaging activation during a working memory task in the same participants; and (3) examine the relationship between positron emission tomographic and functional magnetic resonance imaging outcome measures. DESIGN, SETTING AND PARTICIPANTS Positron emission tomographic imaging with carbon 11-labeled FLB457 before and following 0.5 mg/kg of amphetamine by mouth. Blood oxygenation level-dependent functional magnetic resonance imaging during the self-ordered working memory task. Twenty patients with schizophrenia recruited from the inpatient and outpatient research facilities at New York State Psychiatric Institute and 21 healthy control individuals participated, and data were acquired between June 16, 2011, and February 25, 2014. MAIN OUTCOMES AND MEASURE The percentage change in binding potential (∆BPND) in the DLPFC following amphetamine, BOLD activation during the self-ordered working memory task compared with the control task, and the correlation between these 2 outcome measures. RESULTS We observed significant differences in the effect of amphetamine on DLPFC BPND (mean [SD], ∆BPND in HC: -7.5% [11%]; SCZ: +1.8% [11%]; P = .01); a generalized blunting in dopamine release in SCZ involving most extrastriatal regions and the midbrain; and a significant association between ∆BPND and BOLD activation in the DLPFC in the overall sample including patients with SCZ and HC individuals. CONCLUSIONS AND RELEVANCE To our knowledge, these results provide the first in vivo evidence for a deficit in the capacity for dopamine release in the DLPFC in SCZ and suggest a more widespread deficit extending to many cortical and extrastriatal regions including the midbrain. This contrasts with the well-replicated excess in dopamine release in the associative striatum in SCZ and suggests a differential regulation of striatal dopamine release in associative striatum vs extrastriatal regions. Furthermore, dopamine release in the DLPFC relates to working memory-related activation of this region, suggesting that blunted release may affect frontal cortical function.
Collapse
Affiliation(s)
- Mark Slifstein
- Columbia University, Department of Psychiatry,New York State Psychiatric Institute
| | | | | | - Judy L. Thompson
- Columbia University, Department of Psychiatry,New York State Psychiatric Institute,The State University of New Jersey, Rutgers
| | - Rajesh Narendran
- University of Pittsburgh Medical Center Department of Psychiatry
| | - Roberto Gil
- Columbia University, Department of Psychiatry,New York State Psychiatric Institute
| | | | - Ragy Girgis
- Columbia University, Department of Psychiatry,New York State Psychiatric Institute
| | | | - Holly Moore
- Columbia University, Department of Psychiatry,New York State Psychiatric Institute
| | - Deepak D’Souza
- Yale University School of Medicine Department of Psychiatry
| | | | - Yiyun Huang
- Yale University School of Medicine PET Center,Yale University School of Medicine Department of Diagnostic Radiology
| | - Keun-poong Lim
- Yale University School of Medicine PET Center,Yale University School of Medicine Department of Diagnostic Radiology
| | - Nabeel Nabulsi
- Yale University School of Medicine PET Center,Yale University School of Medicine Department of Diagnostic Radiology
| | - Richard E. Carson
- Yale University School of Medicine PET Center,Yale University School of Medicine Department of Diagnostic Radiology
| | - Jeffery A. Lieberman
- Columbia University, Department of Psychiatry,New York State Psychiatric Institute
| | - Anissa Abi-Dargham
- Columbia University, Department of Psychiatry,Columbia University, Department of Radiology,New York State Psychiatric Institute
| |
Collapse
|
43
|
Ridler K, Cunningham V, Huiban M, Martarello L, Pampols-Maso S, Passchier J, Gunn RN, Searle G, Abi-Dargham A, Slifstein M, Watson J, Laruelle M, Rabiner EA. An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M 1) positive allosteric modulator in the living human brain using positron emission tomography. EJNMMI Res 2014; 4:66. [PMID: 26116126 PMCID: PMC4452589 DOI: 10.1186/s13550-014-0066-y] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2014] [Accepted: 11/11/2014] [Indexed: 12/21/2022] Open
Abstract
Background The ability to quantify the capacity of a central nervous system (CNS) drug to cross the human blood-brain barrier (BBB) provides valuable information for de-risking drug development of new molecules. Here, we present a study, where a suitable positron emission tomography (PET) ligand was not available for the evaluation of a potent muscarinic acetylcholine receptor type-1 (M1) allosteric agonist (GSK1034702) in the primate and human brain. Hence, direct radiolabelling of the novel molecule was performed and PET measurements were obtained and combined with in vitro equilibrium dialysis assays to enable assessment of BBB transport and estimation of the free brain concentration of GSK1034702 in vivo. Methods GSK1034702 was radiolabelled with 11C, and the brain distribution of [11C]GSK1034702 was investigated in two anaesthetised baboons and four healthy male humans. In humans, PET scans were performed (following intravenous injection of [11C]GSK1034702) at baseline and after a single oral 5-mg dose of GSK1034702. The in vitro brain and plasma protein binding of GSK1034702 was determined across a range of species using equilibrium dialysis. Results The distribution of [11C]GSK1034702 in the primate brain was homogenous and the whole brain partition coefficient (VT) was 3.97. In contrast, there was mild regional heterogeneity for GSK1034702 in the human brain. Human whole brain VT estimates (4.9) were in broad agreement with primate VT and the fP/fND ratio (3.97 and 2.63, respectively), consistent with transport by passive diffusion across the BBB. Conclusion In primate and human PET studies designed to evaluate the transport of a novel M1 allosteric agonist (GSK1034702) across the BBB, we have demonstrated good brain uptake and BBB passage consistent with passive diffusion or active influx. These studies discharged some of the perceived development risks for GSK1034702 and provided information to progress the molecule into the next stage of clinical development. Trial registration Clinical trial details: ‘Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study.’; clinicaltrial.gov identifier: NCT00937846. Electronic supplementary material The online version of this article (doi:10.1186/s13550-014-0066-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Khanum Ridler
- Clinical Imaging Centre, GlaxoSmithKline, Burlington Danes Building, Hammersmith Hospital, Du Cane Road, London, UK,
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Van Snellenberg JX, Slifstein M, Read C, Weber J, Thompson JL, Wager TD, Shohamy D, Abi-Dargham A, Smith EE. Dynamic shifts in brain network activation during supracapacity working memory task performance. Hum Brain Mapp 2014; 36:1245-64. [PMID: 25422039 DOI: 10.1002/hbm.22699] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2014] [Revised: 10/23/2014] [Accepted: 11/17/2014] [Indexed: 11/11/2022] Open
Abstract
Despite significant advances in understanding how brain networks support working memory (WM) and cognitive control, relatively little is known about how these networks respond when cognitive capabilities are overtaxed. We used a fine-grained manipulation of memory load within a single trial to exceed WM capacity during functional magnetic resonance imaging to investigate how these networks respond to support task performance when WM capacity is exceeded. Analyzing correct trials only, we observed a nonmonotonic (inverted-U) response to WM load throughout the classic WM network (including bilateral dorsolateral prefrontal cortex, posterior parietal cortex, and presupplementary motor areas) that peaked later in individuals with greater WM capacity. We also observed a relative increase in activity in medial anterior prefrontal cortex, posterior cingulate/precuneus, and lateral temporal and parietal regions at the highest WM loads, and a set of predominantly subcortical and prefrontal regions whose activation was greatest at the lowest WM loads. At the individual subject level, the inverted-U pattern was associated with poorer performance while expression of the early and late activating patterns was predictive of better performance. In addition, greater activation in bilateral fusiform gyrus and right occipital lobe at the highest WM loads predicted better performance. These results demonstrate dynamic and behaviorally relevant changes in the level of activation of multiple brain networks in response to increasing WM load that are not well accounted for by present models of how the brain subserves the cognitive ability to hold and manipulate information on-line.
Collapse
Affiliation(s)
- Jared X Van Snellenberg
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York; Division of Translational Imaging, New York State Psychiatric Institute, New York, New York
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Thompson JL, Rosell DR, Slifstein M, Girgis RR, Xu X, Ehrlich Y, Kegeles LS, Hazlett EA, Abi-Dargham A, Siever LJ. Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112. Psychopharmacology (Berl) 2014; 231:4231-40. [PMID: 24781514 PMCID: PMC4194223 DOI: 10.1007/s00213-014-3566-6] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Accepted: 03/31/2014] [Indexed: 10/25/2022]
Abstract
RATIONALE Schizotypal personality disorder (SPD) is associated with working memory (WM) impairments that are similar to those observed in schizophrenia. Imaging studies have suggested that schizophrenia is associated with alterations in dopamine D1 receptor availability in the prefrontal cortex (PFC) that may be related to the WM impairments that characterize this disorder. OBJECTIVES The aim of this study was to characterize prefrontal D1 receptor availability and its relation to WM performance in SPD. METHODS We used positron emission tomography (PET) and the radiotracer [(11)C]NNC112 with 18 unmedicated SPD and 21 healthy control participants; as an index of D1 receptor availability, binding potential (BP) measures (BPF, BPND, and BPP) were calculated for prefrontal and striatal subregions. To assess WM, SPD participants completed the 2-back and Paced Auditory Serial Addition Test (PASAT). RESULTS There were no significant group differences in PFC BP. BPF and BPP in the medial PFC were significantly negatively related to PASAT performance (r s = -0.551, p = .022 and r s = -0.488, p = .047, respectively), but BP was not related to 2-back performance. CONCLUSIONS In contrast to what has been found in schizophrenia, SPD was not associated with significant alterations in prefrontal D1 receptor availability. Similar to previous schizophrenia findings, however, higher prefrontal D1 receptor availability was associated with poorer WM performance (as measured by the PASAT) in SPD. These findings suggest that schizophrenia and SPD may share a common pathophysiological feature related to prefrontal dopamine functioning that contributes to WM dysfunction, but that in SPD, alterations in D1 may occur only in a subset of individuals and/or to an extent that is minor relative to what occurs in schizophrenia.
Collapse
Affiliation(s)
- Judy L. Thompson
- Department of Psychiatry, Columbia University College of Physicians and
Surgeons, New York, NY, 10032
| | - Daniel R. Rosell
- Department of Psychiatry, Mount Sinai School of Medicine, New York, NY,
10029,James J. Peters Veterans Affairs Medical Center, Bronx, NY, 10468
| | - Mark Slifstein
- Department of Psychiatry, Columbia University College of Physicians and
Surgeons, New York, NY, 10032
| | - Ragy R. Girgis
- Department of Psychiatry, Columbia University College of Physicians and
Surgeons, New York, NY, 10032
| | - Xiaoyan Xu
- Department of Psychiatry, Columbia University College of Physicians and
Surgeons, New York, NY, 10032
| | - Yosefa Ehrlich
- Department of Psychiatry, Mount Sinai School of Medicine, New York, NY,
10029,James J. Peters Veterans Affairs Medical Center, Bronx, NY, 10468
| | - Lawrence S. Kegeles
- Department of Psychiatry, Columbia University College of Physicians and
Surgeons, New York, NY, 10032,Department of Radiology, Columbia University College of Physicians and
Surgeons, New York, NY, 10032
| | - Erin A. Hazlett
- Department of Psychiatry, Mount Sinai School of Medicine, New York, NY,
10029,James J. Peters Veterans Affairs Medical Center, Bronx, NY, 10468
| | - Anissa Abi-Dargham
- Department of Psychiatry, Columbia University College of Physicians and
Surgeons, New York, NY, 10032,Department of Radiology, Columbia University College of Physicians and
Surgeons, New York, NY, 10032
| | - Larry J. Siever
- Department of Psychiatry, Mount Sinai School of Medicine, New York, NY,
10029,James J. Peters Veterans Affairs Medical Center, Bronx, NY, 10468
| |
Collapse
|
46
|
Luo SX, Martinez D, Carpenter KM, Slifstein M, Nunes EV. Multimodal predictive modeling of individual treatment outcome in cocaine dependence with combined neuroimaging and behavioral predictors. Drug Alcohol Depend 2014; 143:29-35. [PMID: 25108585 PMCID: PMC4358761 DOI: 10.1016/j.drugalcdep.2014.04.030] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2014] [Revised: 04/11/2014] [Accepted: 04/21/2014] [Indexed: 02/08/2023]
Abstract
BACKGROUND Developing personalized treatments for cocaine dependence remains a significant clinical challenge. Positron emission tomography (PET) has shown that the [(11)C]raclopride signal in the ventral striatum is associated with treatment success in a positively reinforced contingency management program. The present study investigates whether this signal can be used to predict treatment outcome at an individual level. METHODS Predictive models were developed using PET signals from 5 regions of the striatum and follow-up data in 24 patients, and evaluated using cross-validation. RESULTS The ventral striatal PET signal alone can predict individual treatment response with a substantial degree of accuracy (cross-validated correct rate=82%). Incorporating information from other regions-of-interest (ROIs) in the striatum does not improve predictive performance, except for a small improvement with adding the posterior caudate. The addition of baseline demographic variables, including baseline severity measures, does not improve predictive performance. On the other hand, early treatment response and motivation, reflected by cumulative clinic attendance, performs as well as the PET signal (83%) by week 3 in the 24-week study. The combined model with both PET signals and cumulative clinic attendance demonstrates a significant improvement of performance, peaking at 96% during week 3 of the trial. CONCLUSIONS These results suggest that a multimodal model can predict treatment success in cocaine dependence at an individual level, and pose hypotheses for the underlying neural circuitry mechanisms responsible for individual variations in treatment outcome.
Collapse
Affiliation(s)
- Sean X. Luo
- Division of Substance Abuse, Department of Psychiatry, New York State Psychiatric Institute, Columbia University. 1051 Riverside Drive #32, New York, NY 10032
| | - Diana Martinez
- Division of Substance Abuse, Department of Psychiatry, New York State Psychiatric Institute, Columbia University. 1051 Riverside Drive #32, New York, NY 10032
| | - Kenneth M. Carpenter
- Division of Substance Abuse, Department of Psychiatry, New York State Psychiatric Institute, Columbia University. 1051 Riverside Drive #32, New York, NY 10032
| | - Mark Slifstein
- Division of Substance Abuse, Department of Psychiatry, New York State Psychiatric Institute, Columbia University. 1051 Riverside Drive #32, New York, NY 10032
| | - Edward V Nunes
- Division of Substance Abuse, Department of Psychiatry, New York State Psychiatric Institute, Columbia University. 1051 Riverside Drive #32, New York, NY 10032
| |
Collapse
|
47
|
Hwang DR, Hu E, Rumfelt S, Easwaramoorthy B, Castrillon J, Davis C, Allen JR, Chen H, Treanor J, Abi-Dargham A, Slifstein M. Initial characterization of a PDE10A selective positron emission tomography tracer [11C]AMG 7980 in non-human primates. Nucl Med Biol 2014; 41:343-9. [PMID: 24607437 DOI: 10.1016/j.nucmedbio.2014.01.007] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Revised: 12/19/2013] [Accepted: 01/07/2014] [Indexed: 10/25/2022]
Abstract
INTRODUCTION Phosphodiesterase 10A (PDE10A) is an intracellular enzyme responsible for the breakdown of cyclic nucleotides which are important secondary messengers in the central nervous system. Inhibition of PDE10A has been identified as a potential therapeutic target for treatment of various neuropsychiatric disorders. To assist the drug development program, we have identified a selective PDE10A PET tracer, [(11)C]AMG 7980, for imaging PDE10A distribution using positron emission tomography. METHODS [(11)C]AMG 7980 was prepared in a one-pot, two-step reaction. Dynamic PET scans were performed in non-human primates following a bolus or bolus plus constant infusion tracer injection paradigm. Regions-of-interest were defined on individuals' MRIs and transferred to the co-registered PET images. Data were analyzed using Logan graphical analysis with metabolite-corrected input function, the simplified reference tissue model (SRTM) method and occupancy plots. A benchmark PDE10A inhibitor was used to demonstrate PDE10A-specific binding. RESULTS [(11)C]AMG 7980 was prepared with a mean specific activity of 99 ± 74 GBq/μmol (n=10) and a synthesis time of 45 min. Specific binding of the tracer was localized to the striatum and globus pallidus (GP) and low in other brain regions. Thalamus was used as the reference tissue to derive binding potentials (BPND). The BPND for caudate, putamen, and GP were 0.23, 0.65, 0.51, respectively by the graphical method, and 0.42, 0.76, and 0.75 from the SRTM method. A dose dependent decrease of BPND was observed with the pre-treatment of a PDE10A inhibitor. A bolus plus infusion injection paradigm yielded similar results. CONCLUSION [(11)C]AMG 7980 has been successfully used for imaging PDE10A in non-human primate brain. Despite the fast brain kinetics it can be used to measure target occupancy of PDE10A inhibitors in non-human primates and potentially applicable to humans.
Collapse
Affiliation(s)
- Dah-Ren Hwang
- Department of Medical Sciences, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States.
| | - Essa Hu
- Department of Small Molecule Chemistry, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Shannon Rumfelt
- Department of Small Molecule Chemistry, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Balu Easwaramoorthy
- Department of Psychiatry, Columbia University, New York, NY, USA; New York State Psychiatric Institute, NY, USA
| | | | - Carl Davis
- Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Jennifer R Allen
- Department of Small Molecule Chemistry, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Hang Chen
- Department of Neuroscience, Amgen Inc., South San Francisco, CA
| | - James Treanor
- Department of Neuroscience, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Anissa Abi-Dargham
- Department of Psychiatry, Columbia University, New York, NY, USA; Department of Radiology, Columbia University, New York, NY, USA; New York State Psychiatric Institute, NY, USA
| | - Mark Slifstein
- Department of Psychiatry, Columbia University, New York, NY, USA; New York State Psychiatric Institute, NY, USA
| |
Collapse
|
48
|
Martinez D, Slifstein M, Nabulsi N, Grassetti A, Urban N, Perez A, Liu F, Lin SF, Ropchan J, Mao X, Kegeles LS, Shungu DC, Carson RE, Huang Y. Imaging glutamate homeostasis in cocaine addiction with the metabotropic glutamate receptor 5 positron emission tomography radiotracer [(11)C]ABP688 and magnetic resonance spectroscopy. Biol Psychiatry 2014; 75:165-71. [PMID: 24035345 PMCID: PMC4106018 DOI: 10.1016/j.biopsych.2013.06.026] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Revised: 06/05/2013] [Accepted: 06/28/2013] [Indexed: 12/22/2022]
Abstract
BACKGROUND Preclinical studies demonstrate that glutamate homeostasis in the striatum is disrupted following cocaine exposure, including a decrease in metabotropic glutamate receptor type 5 (mGluR5) expression and reduced glutamate turnover. The goal of this study was to use imaging of the human brain to investigate alterations in the glutamate signaling in cocaine addiction. METHODS Positron emission tomography imaging with the radiotracer [(11)C]ABP688 was used to measure mGluR5 binding and magnetic resonance spectroscopy was used to measure glutamate-glutamine levels in the striatum of cocaine-addicted participants (n = 15) compared with healthy control subjects (n = 15). Following the scans, the cocaine-addicted volunteers performed cocaine self-administration sessions to investigate the correlation between cocaine-seeking behavior and mGluR5 receptor binding. RESULTS The results of the study showed that cocaine addiction was associated with a 20% to 22% reduction in [(11)C]ABP688 binding in the striatum. A secondary analysis of cortical and subcortical regions other than the striatum showed a similar reduction in [(11)C]ABP688 binding, suggesting that the decrease was widespread. No between-group differences were seen in the magnetic resonance spectroscopy measures of glutamate-glutamine in the left striatum. In addition, no correlation was seen between [(11)C]ABP688 binding in the striatum and the choice to self-administer cocaine. CONCLUSIONS Overall, these results show that long-term cocaine use is associated with a decrease in mGluR5 availability compared with matched healthy control subjects and suggests that this receptor may serve as a viable target for treatment development for this disorder.
Collapse
Affiliation(s)
- Diana Martinez
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, New York.
| | - Mark Slifstein
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, NY, USA
| | - Nabeel Nabulsi
- The Department of Psychiatry, Yale PET Center, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Alexander Grassetti
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, NY, USA
| | - Nina Urban
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, NY, USA
| | - Audrey Perez
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, NY, USA
| | - Fei Liu
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, NY, USA
| | - Shu-fei Lin
- The Department of Psychiatry, Yale PET Center, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Jim Ropchan
- The Department of Psychiatry, Yale PET Center, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Xiangling Mao
- Department of Radiology, Weill Medical College of Cornell University, New York, NY, USA
| | - Lawrence S. Kegeles
- Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, NY, USA
| | - Dikoma C. Shungu
- Department of Radiology, Weill Medical College of Cornell University, New York, NY, USA
| | - Richard E. Carson
- The Department of Psychiatry, Yale PET Center, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Yiyun Huang
- The Department of Psychiatry, Yale PET Center, Yale University School of Medicine, New Haven, Connecticut, USA
| |
Collapse
|
49
|
Poels EMP, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 2014; 19:20-9. [PMID: 24166406 DOI: 10.1038/mp.2013.136] [Citation(s) in RCA: 144] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2013] [Revised: 08/25/2013] [Accepted: 09/09/2013] [Indexed: 12/11/2022]
Abstract
Currently, all treatments for schizophrenia (SCZ) function primarily by blocking D(2)-type dopamine receptors. Given the limitations of these medications, substantial efforts have been made to identify alternative neurochemical targets for treatment development in SCZ. One such target is brain glutamate. The objective of this article is to review and synthesize the proton magnetic resonance spectroscopy ((1)H MRS) and positron emission tomography (PET)/single-photon emission computed tomography (SPECT) investigations that have examined glutamatergic indices in SCZ, including those of modulatory compounds such as glutathione (GSH) and glycine, as well as data from ketamine challenge studies. The reviewed (1)H MRS and PET/SPECT studies support the theory of hypofunction of the N-methyl-D-aspartate receptor (NMDAR) in SCZ, as well as the convergence between the dopamine and glutamate models of SCZ. We also review several advances in MRS and PET technologies that have opened the door for new opportunities to investigate the glutamate system in SCZ and discuss some ways in which these imaging tools can be used to facilitate a greater understanding of the glutamate system in SCZ and the successful and efficient development of new glutamate-based treatments for SCZ.
Collapse
Affiliation(s)
- E M P Poels
- 1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA
| | - L S Kegeles
- 1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA
| | - J T Kantrowitz
- 1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA
| | - M Slifstein
- 1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA
| | - D C Javitt
- 1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA
| | - J A Lieberman
- 1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA
| | - A Abi-Dargham
- 1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA [3] Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - R R Girgis
- 1] Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA [2] New York State Psychiatric Institute, New York, NY, USA
| |
Collapse
|
50
|
Abstract
The cellular mechanisms of alcohol's effects in the brain are complex, targeting multiple transmitter systems. Molecular imaging has been used to study the effects of alcohol and alcohol use disorders on these various systems. Studies of dopaminergic indices have provided robust evidence for deficits in D2-mediated transmission in the striatum of chronic recently detoxified alcoholics. Their presence in the at-risk state prior to excessive drinking, and their recovery after long-term sobriety, are unclear and represent an active area of current research. Investigations of the GABAergic system have shown generalized deficits in various brain regions in the chronic abstinence phase. Studies of the opiate system have suggested alterations in some subtypes in discrete brain regions, including the ventral striatum, while studies of serotonin have been negative and those of the cannabinoid system have been inconclusive. Future investigations should target the glutamatergic system, which plays an important role both in the acute intoxicating effects of alcohol as well as in the long-term effects associated with dependence.
Collapse
Affiliation(s)
- Shervin Ravan
- Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - Diana Martinez
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - Mark Slifstein
- Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA
| | - Anissa Abi-Dargham
- Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY, USA; Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA.
| |
Collapse
|